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SUMMARY
Ill
Sixteen patients with cystic fibrosis were monitored for 
eighteen months by monthly bacteriological examination of nose 
and throat swabs and sputum in order to determine if better 
control of respiratory infection could be achieved by more 
rational usage of antibiotics.
The patients were divided into two groups; a Variable 
Antibiotic group and a Flucloxacillin group. The first 
group received only one antibiotic which was initially chosen 
and then changed as culture results dictated, while the second 
group was given continuous anti-staphylococcal chemoprophylaxis 
plus one other antibiotic if required, but the latter for a 
period of 10 days only.
Weight, height, and radiological data showed that in both 
groups of patients the clinical status did hot alter significantly 
from the start of the investigation, although no deterioration 
was observed. However, the number of hospital admissions, 
which reflected exacerbation of pulmonary infection, was greatly 
reduced in both groups during the 18 months of the investigation.
The predominant organism isolated from both groups was 
Staphylococcus aureus. However, in patients with severe 
pulmonary involvement, both S. aureus and Pseudomonas aeruginosa 
occurred. This agrees with previous findings that the main 
organisms associated with respiratory problems in CF patients 
are S. aureus and P . aeruginosa, despite the presence of other 
bacterial species in the respiratory tract.
Control of S. aureus and Haemophilus influenzae infection 
was significantly better in the Flucloxacillin group, but
XV
neither these organisms nor P. aeruginosa were completely 
era dicated.
Antibiotic sensitivity tests indicated that bacterial 
isolates from CF patients were, in general, more sensitive 
to antibiotics than the same species from non-CF patients.
This greater incidence of antibiotic-susceptible bacterial 
isolates from CF patients, as compared with non-CF patients 
in a children's hospital, has not previously been reported.
This lesser degree of antibiotic resistance was thought to 
be due to lower selection pressure on the organisms.
The mucoid strain of P. aeruginosa showed greater 
susceptibility to certain antibiotics than the rough strain - 
a point on which previous investigations have been divided.
Phage-typing of the S. aureus isolates from the CF patients 
revealed that the upper respiratory tract was not the source of 
this organism in pulmonary infection. No evidence was found 
to suggest the predominance of any single phage-type, although 
each patient usually harboured S. aureus from one phage-group.
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INTRODUCTION
History and Incidence of Cystic Fibrosis
Cystic fibrosis (CF) is the most common lethal genetic 
disorder of Caucasians and is the cause of much of the chronic 
progressive lung disease present in children and young adults.
The incidence of CF in European countries is generally accepted 
as 1 in 2000 live births (di Sant' Agnese and Talamo, 1967),
CF was reported for the first time by Faneoni 0‘^3t0.
He described the relationship of "bronchiectasis” and congenital 
cystic pancreatic fibrosis.
However, cystic fibrosis was not recognised as a separate 
and distinct disorder until the extensive work of Andersen (1938) 
This was the first detailed pathological description of the 
disease. She termed the disorder "fibrocystic disease of the 
pancreas" because of the marked fibrosis and dilated ducts in 
the pancreas gland. Her work showed the clear association of 
pancreatic pathology with widespread pulmonary infection.
These findings were confirmed by Blackfan and May (1938) 
and the modified term "cystic fibrosis of the pancreas" came 
into use.
CF is also known as "mucoviscidosis", This term was 
coined by Farber (1945). He chose this name since he thought 
that it described the basic defect viz an abnormality of 
mucous secretions.
CF is expressed only in the homozygous state without 
X-linkage. Both sexes are therefore affected with equal
frequency. Parents, who are normally heterozygous, are 
unaffected.
Until recently, CF was believed to be transmitted as an 
autosomal recessive trait. Schaap and Cohen (1976), however, 
have proposed that CF is determined by dominant alleles at two 
autosomal loci, with interaction between them.
CF is not genetically linked with ABH blood group substances 
(Virtanen, 1966) MNS blood groups (Steinberg and Morton, 1956) 
or HLA antigens (Polymenidis, Ludwig and Gotz, 1973).
The patient with CF presents with chronic chest disease, 
pancreatic insufficiency with steatorrhoea, azotorrhoea, 
malnutrition and growth failure, and abnormally high sweat sodium 
levels. Some or all of the symptoms are present from birth.
The degree of progression of both pulmonary and gastrointestinal 
symptoms is very variable.
Until the advent of antibiotics and a greater understanding 
of the underlying effects of the defect of CF, life expectancy 
was short. In 1955 50 per cent of CF patients were expected 
to live until 4 years of age; whereas, in 1975, this age had 
increased to 17 years.
A recent report by Warwick and Pogue (1977) gives an even 
more optimistic prognosis for the future. The authors point 
out that although it is true that CF patients who reach 18 years 
of age have a shorter life span than their "normal" counterparts, 
this must be placed in perspective. Data from the CF registry 
of Warwick and Pogue show the median life expectancy for patients 
15 years of age and older to be more than 11 years. This 
indicates a better survival than that for leukaemia.
Diagnosis
There are four criteria currently in use for the diagnosis 
of CF (l) Chronic obstructive pulmonary disease; (2) Exocrine 
pancreatic insufficiency; (3) Family history of CF; (4) A 
positive sweat test (i.e. > 60mEql ^ Na*). Most clinics 
require at least 2 of the above criteria for a diagnosis. 
However, a diagnosis is rarely made in the absence of a positive 
sweat test.
Several methods of collecting body sweat have been used
and discarded for various reasons. The most reliable, widely
accepted, and safest method is by the induction of localized 
sweating by pilocarpine iontophoresis (Gibson and Cook^ 1959).
At least lOOmg of sweat must be collected for accurate determin­
ation using this method.
Pathophysiology of Cystic Fibrosis
Despite documentation of many of the characteristic 
symptoms of CF the basic defect is still unknown.
There is a general pattern to the condition. Much of the
pathology results from the change in the nature of mucous and 
serous secretions which occurs throughout the body. The 
former are abnormally sticky or dry and the latter concentrated. 
The secretions are therefore hard to disperse and consequently 
block ducts or ductules. The blockage of ducts is apparent in 
a number of organs but is particularly important in the lungs 
and pancreas where it leads to the cardinal clinical features 
of the disease, namely a progressive obstructive suppurative
chest disorder together with malabsorption due predominantly
to an insufficiency of the pancreatic digestive enzyme secretion.
The sweat is the most obviously abnormal of the serous 
secretions in that its sodium and chloride content is 3-4 times 
that of normal sweat.
In the pancreas, secretions precipitate within the lumen 
of the ducts causing blockage and duct dilatation. Destruction 
of exocrine secretory tissue and replacement with fibrous tissue 
then occurs. The alteration of function in most cases is 
maximal at birth and therefore malabsorption is usually present 
from that time.
Unlike the pancreas, the lungs are structurally normal at 
birth, but the bronchioles are soon obstructed by the rather 
viscous mucus. The static mucus in the bronchioles becomes 
infected. Examination of such a mucus plug will show it contains, 
in addition to bacteria, bacterial products, leucocytes, and 
deoxyribonucleic acid. The infected mucus is difficult to 
expectorate and becomes widespread throughout the bronchial tree 
producing an obstructive suppurative chest illness which, if 
untreated, becomes progressive and leads eventually to bronchie­
ctasis, pulmonary fibrosis, and finally cor pulmonale, cardiac 
failure, and death.
Respiratory disease contributes with the nutritional 
deficiency caused by malabsorption in the typical manifestations 
of untreated CF viz chronic productive cough, dyspnoea, clubbing 
of fingers, signs of malnutrition, and abnormally large greasy 
offensive stools.
Chronic respiratory disease is, therefore, the major cause
of morbidity and mortality in CF. It is also the most difficult 
aspect of the condition to treat and control throughout the 
patient's life.
Microbiology of CF
Pathogenic bacteria play a dominant role in the pulmonary 
involvement of patients with CF. These patients usually 
harbour the same pathogenic bacteria for long periods even when 
signs of clinical improvement are evident. Such persistence 
of pathogenic bacteria in the respiratory tract is not generally 
found in patients suffering from chronic respiratory infections 
due to other causes.
As the state of the bronchial secretions plays an important 
role in pulmonary infection perhaps a definition would be 
appropriate at this point.
Bronchial secretion is the liquid lining the tracheobronchial 
tree; when this secretion reaches the larynx, mixes with upper 
respiratory tract secretion and saliva and is expectorated, it is 
known as sputum. The main bulk of sputum representing bronchial 
secretions can be considered to arise from :
i) Mucus-secreting cells of surface epithelium and 
submucosal glands.
ii) Plasma component.
iii) Other specialised cells (e.g. plasma cells, mast cells).
iv) Alveolar surfactant.
The organisms considered to be the main pathogens in CF 
are Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus
Influenzae ( di Sant’ Agnese and Andersen, 194-6; Huang ejb a 1. ,
I96I; lacocca , 1963; di Sant’ Agnese and Talamo, 1967;
Lawson, 1970; May ^  , 1972). Other bacteria including
Streptococci, Klebsiella pneumoniae, Escherichia coli and 
Proteus mirabilis are also found in sputum of CF patients.
The three foremost pathogens in CF have been the cause 
of considerable controversy not only over which causes most 
lung damage but also the order of infection.
The following order was proposed by Burns and May (1968).
1. S. aureus
2. H . influenzae
3. P. aeruginosa
Their reasoning was that S. aureus caused the damage which 
rendered the lungs susceptible to infection.by other species. 
Antibiotics used to control 8. aureus allowed the influx of
H. influenzae. Finally, continued chemotherapy leads to the 
introduction and establishment of P. aeruginosa which ultimately 
supplants the others to become the sole pathogen. This hypothesis
has recently been supported by Kilbourn (1978).
A significant decrease in the frequency of isolation of 
S . aureus has been noted during the past ten to fifteen years 
with a concomitant increase in P. aeruginosa (Mearns et al., 1972). 
Antibiotic therapy is thought to be one cause of change in flora. 
However, in other paediatric situations the incidence of 
infection due to staphylococci has lessened and S. aureus is now 
no longer the predominant organism in neonatal infections.
Mucus would appear to be a contributing factor in the 
pathogenicity of S. aureus (lacocca ct a_l., 1963). The mucus
may act as a protective coating for the organisms, effectively
preventing penetration of antibodies and inhibiting leucocytic 
invasion. On the other hand, if the bacteria are surrounded by 
a mucus envelope it may act as a barrier for the host by confining 
infection to the lungs.
There is no evidence that bronchial secretions in CF have 
a growth promoting factor for S. aureus (Eichenwald, I960).
F. aeruginosa has probably aroused most interest of the 3 
organisms. There are 2 strains of this organism; a rough
strain and a mucoid strain which is peculiar to CF. The non­
mucoid strain of the organism always proceeds the mucoid form 
(Dbggett e_t aJ.., 1966). The latter is commonly the predominant 
and usually only organism found in the lungs at post mortem.
A carrier state was found exclusively in patients with CF 
(Laraya-Cuasay ^  ^ ., 1976). Although most of the patients 
studied by these workers were persistant pharyngeal carriers 
of P. aeruginosa the organism was not isolated from nasal cultures
. There are 3 factors which are believed to predispose patients 
with CF to infection by P. aeruginosa
1. Antibiotic therapy. The frequent and prolonged use of 
antibiotics in these patients favours the persistence of 
Pseudomonas. However, in some cases P. aeruginosa is the 
initial pathogen.
2. Hospitalization. Equipment contaminated with P. aeruginosa 
e.g. inhalation equipment.
3. Intrinsic factors. Obstruction of bronchioles by
tenacious mucus, and impairment of mucociliary clearance.
This latter factor, equally applicable to S. aureus, 
raises the question of an impaired immune system rendering CF 
patients susceptible to infection.
Extra-pulmonary infection is rare and CF patients are not 
more prone to infections outside the respiratory tract than 
normal subjects of the same age. This suggests a defect in 
local rather than systemic defence mechanisms. Local defence 
mechanisms in the lung include phagocytosis, mucociliary transport, 
and immunoglobulin secretion.
Impaired phagocytosis by the alveolar macrophage is the 
only inhibitory immune defect reported. This impairment has 
been attributed to defective opsonization (Biggar _et a^., 1971) 
or to a heat-labile inhibitor (Boxerbaum e_t ^1. , 1973).
Biggar and co-workers observed during an assay of 
phagocytosis by rabbit alveolar macrophage that sera from CF 
patients failed to support normal phagocytosis of P. aeruginosa. 
Defective opsonization could be explained by a quantitative or 
functional defect of IgA antibodies specific for Pseudomonas.
Boxerbaum _e_t a_l, , (1973) found that inhibition of phago­
cytosis was specific for Pseudomonas since phagocytosis of 
Staphylococcus and Serratia was normal.
Phagocytic activity by blood leucocytes against Pseudomonas 
was reported to be unaffected (Biggar ejk ±1' , 1971). However, 
it has recently been reported that there is a specific 
unresponsiveness to P. aeruginosa by blood lymphocytes
(Sorensen ejt a_l. , 1977). This suggests that there is a defective 
clearing of P. aeruginosa from the lung since activation of 
pulmonary alveolar macrophage is partly achieved by lymphokines 
secreted by stimulated lymphocytes.
Local immunoglobulins probably play a greater role in CF 
than serum immunoglobulins as infection is localized.
Accordingly several workers have sought a defect in locally 
synthesized secretory IgA, by studying immunoglobulin synthesis 
and levels in the exocrine glands.
Martinez-Tello, Braun, and Blanc (1968) examined post­
mortem bronchial tissues and lymph nodes from patients with 
severe pulmonary diseases, for fluorescein-staining immunoglobulin- 
producing plasma cells. In the CF patients, the number of cells 
containing IgG, IgM, and IgA were normal as was the distribution 
of the secretory piece in IgA.
There is a relation between the severity of the pulmonary 
infections and the immunoglobulin content of sputum (Wallwork 
et al., 1974). This has been observed in other pulmonary 
infections. IgA levels are high in sputum from bronchiec- 
tactics and appreciable amounts of IgE is present in chronic 
bronchitis (Turnbull e_t a_l. , 1977).
It is interesting that most precipitating antibodies in 
sputum are IgG rather than secretory IgA (McFarlane et al.,
1975). This suggests a substantial transudation of serum 
antibody. McFarlane and co-workers also demonstrated the 
deposition of antigen-antibody complexes in the respiratory 
tract. Such complexes may lead to tissue damage.
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Antibody function in CF is not defective. Thus there is 
evidence of serum precipitating antibodies to respiratory 
pathogens notably Pseudomonas (Hjzîiby and Axelsen, 1973), 
Staphylococcus (Halbert, di Sant 'Agnese, and Kutek, I960),
H. influenzae (Halbert, 1967), and Aspergillus fumigatus 
(Schwartz e_t a_l^. , 1970) . Mucoid strains of P. aeruginosa 
are associated with a strong and differentiated humoral immune 
response (Hjzfiby, 1974b). This was indicated by a positive 
correlation between the number of precipitins and the titres 
of the strongest precipitins given by the mucoid strains. Non­
mucoid strains gave significantly fewer precipitins.
Dissention still exists as to the role of P. aeruginosa 
as a pathogen in CF, This organism is regarded as an opportun­
istic pathogen in medical microbiology, and this may be the 
situation in C F .
An organism which is an opportunistic pathogen lacks such 
characteristics as invasiveness and virulence. Before it can 
become pathogenic to a host it has to surmount these deficiencies. 
This is achieved not so much by the organism itself but by a 
combination of factors. These factors are normally a susceptible 
host' and the ability of the opportunistic pathogen to adapt and 
survive in environments hostile to many other bacteria.
The mucoid strain of P, aeruginosa is thought to be the 
result of such an adaptation by the naturally occurring rough 
strain.
The nature of the slime envelope produced by the mucoid 
strain is in itself unusual. It is secreted from the cell as
an exopolysaccharide, a polymer of mannuronic and guluronic
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acids. It resembles that of alginic acid, a seaweed poly­
saccharide (Doggett ^t aj^ . , 1964, 1965, 1966; Linker and 
Jones, 1964; Carlson and Matthews, 1966; Evans and Linker,
1973). The slime envelope differs chemically from the 
bronchial mucus of the lung.
There is no convincing evidence that the slime envelope 
produced by P. aeruginosa is toxic. It is more probable 
that it confers some form of protection on the organism against 
the action of antibiotics or phagocytes (Schwarzmann and Boring, 
1971).
The trigger mechanism of the slime envelope production 
in P. aeruginosa is thought to be the environment of the CF 
lung. Williams and Covan (1973) have shown that mucoid and 
non-mucoid strains isolated from the same patient are of the 
same pyocine type. Thus, infection is not by naturally occurring 
mucoid strains.
Martin (1973) reported the induction of mucoid strains of 
P. aeruginosa by bacteriophage. She observed during routine 
phage typing of P. aeruginosa that in some plates the area 
of lysis was surrounded by a ring of wet, slimy growth.
Subcultures from this slime grew mucoid colonies. The properties
of the phage induced mucoid strains were the same as those from
patients with CF. She concluded that if the mucoid strains in 
the CF lung arose as a result of phage the most likely source was 
other strains of P . aeruginosa.
Little is known of the incidence and survival of such
viruses in the human lung.
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The slime envelope of P. aeruginosa is not, however, 
stable. Mucoid P. aeruginosa rapidly reverts to the non­
mucoid form when cultured vitro (Govan, 1975). In the 
course of Govan's investigations he found that the slime 
envelope could be stabilised for approximately 50 subcultures 
when P. aeruginosa was grown in deoxycholate-citrate agar.
He also found that it could be stabilised when the organism 
was grown in the presence of surfactants similar to those found 
in normal lung e.g. dipalmitoyl lecithin. Dipalmitoyl lecithin 
is the major surfactant found in the human lung. The concen­
tration at which maximum stabilisation occurred was approximately 
the same as that found in the lung. Thus dipalmitoyl lecithin 
may have a significant role in the production of mucoid strains.
Evidence suggests that P. aeruginosa probably has at least 
a secondary influence on the course of respiratory disease in 
CF. In most cases, CF patients tolerate chronic Pseudomonas 
infection since they have built up immunologic defences elsewhere 
in the body. This is in marked contrast to the usual fulminant 
course of Pseudomonas infections in immunosuppressed or burns 
patients.
H. influenzae has aroused interest recently as to its role 
as a pathogen in CF (McCrae and Raeburn, 1974). These authors 
found no evidence of S. aureus in their patients. H. influenzae 
was the commonest pathogen isolated in patients with cough and/or 
sputum. This was replaced in the more severe cases by 
P. aeruginosa.
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Virus Infections in CF
The role of virus infections in CF has received little 
attention. The incidence of these infections appears to he no 
higher than in healthy children, and the prevalence of anti­
bodies in serum no different from normal children (Huang _e_t al., 
1961) .
Viral respiratory infections may, however, exacerbate 
bacterial infection in C F , Measles and influenza can cause 
particularly severe pulmonary involvement. Because of this, 
some workers advocate immunization of CF children against these 
diseases (Wood at aj_., 1976).
Fungus Infections in CF
Fungi such as Candida albicans and Aspergillus fumigatus 
are sometimes isolated from sputum cultures of CF patients.
They are rarely implicated in clinical symptomatology.
Cell-mediated immunity against A. fumigatus has been found 
(Gibbons at a^., 1976; Mitchell-Heggs at aj^ . , 1976). The 
latter group of workers also reported allergic aspergillosis in 
their patients.
Type I and type III hypersensitivity has been shown to 
A. fumigatus (Mearns, Longbottom and Batten, 1967) as well as to 
other antigens including food, bacteria, and human body tissue 
(McFarlane et. ; 1975). Type III hypersensitivity is 
probably responsible for the greater tissue damage, since this 
causes an Arthus reaction resulting in the deposition of immune 
complexes, possibly in the lung (McFarlane et al., 1975).
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Despite increased knowledge gained during the past 10 
years, treatment of CF remains essentially empirical and 
symptomatic. Until the basic defect is known this situation 
seems likely to prevail.
OBJECT OF THE RESEARCH
15
Patients with CF are subject to chronic progressive 
infection of the respiratory tract. Why the CF child is so 
prone to respiratory infection is not known. The copious 
production of viscid mucus in the respiratory tract may be 
one factor only.
The objects of this investigation were
1. To find out if obtaining nose and throat swabs and sputum 
specimens at monthly intervals (which i s m o r e  
frequents, than usual) would lead to better control of 
infection,
2. To assess two methods of treatment in achieving control 
of infection. One method (Flucloxacillin group) 
involved the administering of continuous anti- 
staphylococcal antibiotics plus one other antibiotic if 
required. The other (Variable Antibiotic group) used 
only one antibiotic which was changed as culture results 
dictated .
3. To determine antibiotic sensitivities and resistances 
for all potential pathogens in CF and not only S. aureus,
P. aeruginosa and H. influenzae and to see if those patterns 
changed with time in individual patients.
4- To assess the clinical improvement in the patients 
following therapy for 18 months.
MATERIALS AND METHODS
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Specimens : Specimens were taken at weekly intervals from
the original six patients (AL, D S , IL, TK, YH, H W ) . When 
the nnmher of patients under investigation increased to the 
final total of sixteen, specimens were taken thereafter at 
monthly intervals. Each specimen was collected by the author 
from the patients at home or at school. Nose and throat 
swabs were obtained using serum coated Hospiswabs (Medical 
Wire and Equipment Company Ltd.). Sputum was collected by 
aspiration into sterile plastic universal containers (Sterilin)
Culture Media : Horse Blood agar (Oxoid Columbia agar +
5^ defibMinated horse blood, Gibco Ltd.) was used for the 
isolation of all pathogens; Chocolate Blood agar (Oxoid Blood 
agar Base No. 2, Gibco Ltd.) as the ' 1 ' ■£ for
Haemophilus species, and MacConkey agar (Oxoid Code No. CM7b) 
for Enterobacteriaceae and Pseudomonas aeruginosa.
Culture Procedures : Each specimen was cultured immediately
on return to the hospital laboratory, usually no more than 5 
hours after the specimen was taken,
. Nose and throat swabs were plated directly onto the 
culture media, the media was inoculated using the Hospiswabs 
in the following order :
1. Horse Blood agar
2. Chocolate Blood agar
3. MacConkey agar
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The sputum specimens were extremely viscous. It was 
therefore very difficult to use a platinum loop to plate out 
this material such that a representative culture of the 
specimen was obtained. In order to overcome this problem a 
fresh, sterile Hospiswab was immersed in the most purulent area 
of the sputum. The specimen was cultured using the procedure 
for nose and throat swabs.
The Horse Blood agar was streaked with S. aureus to 
encourage the growth of H. influenzae due to the satellitism 
phenomenon.
The Horse Blood agar and Chocolate Blood agar plates 
were incubated at 37°C in an atmosphere of 5^ CO^. MacConkey 
plates were incubated aerobically at 37°C.
All plates were examined after incubation for 24 hours 
and colonies selected for identification. The primary plates 
were reincubated for a further 24 hours and any further colonies 
removed for identification.
Identification of Bacteria : S . aureus, H . influenzae,
H . parainfluenzas, H. haemolyticus, H. parahaemolyticus, and 
Streptococcus faecalis were identified by the methods outlined 
by Cowan and Steel (1974).
Initial identification of the Enterobacteriaceae was by 
their ability to ferment lactose and, in the case of 
P. aeruginosa produce pigment. Final identification was 
confirmed by the API 20 Enterobacteriaceae (API 20E) System 
(API System S.A.).
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Table 2
Multodisk antibiotic dose
ANTIBIOTIC ABBREVIATION
STANDARD DOSE 
(iLig)
Cotrimoxaz ole SXT 25
Sulphonamide SF 500 and 100*
Be nzylpenicillin P 1.5 units
Ampic illin PN 25
Cloxacillin OB 5
Carbenici11in FY 25
Tetracycline TE 50
Erythromyc in E 10
Cephazolin KZ 30
Cephaloridine CR 30
Cepbradine CE 30
Cephalotbin KF 30
Cephalexin CL 30
Colistin CT 10
Gentamicin CN 10
Tobramyc in TOB 10
Neomycin N 30
Kanamycin K 30
Lincomycin MY 2
Fusidic Acid FD 10
500^g used for gram negative organisms 
lOO^g used for gram positive organisms
20
Definition of a Pathogen : For convenience of discussing
results in this investigation, any organism Isolated from 
the sputum of a patient was regarded as a pathogen or 
potential pathogen and is described as "a pathogen".
The same organism, if isolated from a no-sputum producer, 
was treated similarly. All other organisms were regarded 
as non-pathogens or commensals.
Determination of Antibiotic Sensitivity ; The antibiotic 
sensitivity of each isolate was determined using the disk 
diffusion technique. Commercially prepared disks (Multodisk, 
Oxoid) impregnated with various antibiotics (Table 1) at 
standard concentrations (Table 2) were placed on the centre 
of inoculated Diagnostic Sensitivity Test agar (DST, Oxoid).
The Haemophilus species with their more fastidious growth 
requirements were grown on Chocolate Blood agar. However, 
the diffusion of the sulphonamides is inhibited by this medium. 
They were tested on DST agar although actual growth of the 
organisms was poor.
Note, for brevity in this thesis, all antimicrobial drugs are 
referred to as "antibiotics". This includes sulphonamide and 
cotrimoxazole which are technically not antibiotics in the true 
sense of the word i.e. an antimicrobial agent of microbial 
origin. However, in this day of semi-synthetic antibiotics 
it was felt that to differentiate between the sulphonamides 
and "true" antibiotics would merely be pedantic.
21
Table 3
Order of choice of Antibiotics
Staphylococcus
ORGANISM
Pseudomonas Haemophilus influenzae
aureus aeruginosa AND OTHER Haemophilus 
spe cies
Cloxacillin Gentamicin ^ Cotrimoxaz ole
Erythromyc in Tobramycin J Ampi c illin
Cotrimoxaz ole Colistin Erythromycin
Cephra dine Ampkacin
Clindamycin Tetra cycline
Fusidic Acid
Ampic illin
22
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S . aureus , H. influenzae, H. parainfluenzas, H. haemolyticus, 
and H. parahaemolyticus were tested using disks 5789E, 4798E and 
5675s, P . aeruginosa, P r . mirabilis, E . coli and St. faecalis 
using disks U2 , 5678S and 5675S cXtrdu
Selection and Dose of Antibiotics; The antibiotic for therapy 
was selected from the results of the antibiotic sensitivity tests, 
and in accordance with the pre-designed sequence (Table 3).
Antibiotic dose was determined following consultation with 
Dr. Hamilton and the hospital Pharmacist (Table 4).
The antibiotics actually used in therapy were :
Cloxacillin (Orbenin) Beecham Pharmaceuticals Ltd.
Flucloxacillin (Floxapen) Beecham Pharmaceuticals Ltd.
Ampicillin (Penbritin) Beecham Pharmaceuticals Ltd.
Erythromycin (Erythrocin) Abbott Laboratories Ltd.
Coxtrimoxazole (Septrin) Burroughs Wellcome & Co.
Cephradine (Velosef) E.R. Squibb & Sons Ltd.
Gentamicin (Genticin) Nicholas Laboratories Ltd,
Tobramycin (Nebcin) Lilly Eli & Co. Ltd.
Distribution of Antibiotics : The parents (usually the
mother) of the patients were informed of the results of the 
specimen cultures either by telephone or by letter. They were 
also told which antibiotics to give their child and the dose 
(this was also printed on the label of the bottle).
The antibiotic was sent from the hospital pharmacy to 
the patients’ home or the author telephoned the patient’s
general practitioner from whom the prescription was obtained.
Table 5
Age and sex distribution of cystic fibrosis patients
24
GROUP PATIENT AGE (years) SEX
TK 1.5 F
LC 1.8 F
AL 2.5 F
HW 3.6 M
VARIABLE
IL 7.6 M
ANTIBIOTIC
JD  ^10.3 M
ER , 10.8 F
EB 10.8 M
D8 11.7 M
JG 12.1 M
MEDIAN 8.5
AT 3.8 M
YH 4.8 F
DB 6 .4 M
PA .
FLUCLOXACILLIN
8,2 M
LM 10.3 F
DA ' 16.3 M
MEDIAN 7.3
25
Phage-typing : The phage-typing of S. anrens was carried out
by the phage-typing laboratory at Gartnavel General Hospital, 
Glasgow.
Patients : The patients in this study were chosen,at random,
from the cystic fibrosis patients attending Wards 6a, 6b,
7a and 7b of the Royal Hospital for Sick Children, Glasgow,
The total number of patients selected was 20.
Parental permission was sought prior to commencing therapy 
This was refused in 4 cases.
The remaining 16 patients were divided into 2 groups 
(Table 5).
Variable Antibiotic Group : These patients were drawn from
Wards 7a and 7b. When the results of the specimen cultures 
were known, an appropriate antibiotic was prescribed from the 
pre-designed sequence. The patients were kept on this 
antibiotic until either future cultures indicated a new 
pathogen was present which was resistant to the antibiotic, 
or, that the present pathogen, itself, had become resistant.
The exception to this procedure occurred if an amino­
glycoside (tobramycin or gentamicin) was prescribed. As 
these drugs can be toxic, therapy was only given for 10 days, 
whereafter the patient was returned to the anti-staphylococcal 
antibiotic (Cloxacillin).
26
Flucloxacillin Group : The patients in this group were drawn
from Wards 6a and 6h . These patients were always treated 
with an anti-staphylococcal antibiotic (Flucloxacillin).
If culture indicated the presence of a pathogenic organism 
which was resistant to this drug, a second appropriate antibiotic 
was administered concurrently with the Flucloxacillin. This 
second antibiotic, however, was only given for a period of 10 
days .
A record consisting of the type of specimen, the organisms 
isolated, the antibiotic sensitivities, and the antibiotic 
choice was kept for each patient in the 2 groups.
Measurement of Weight and Height ; Weight and height were 
measured on each visit to the hospital clinic. The technique 
for both was that recommended by Tanner ejb a_l. , (1966).
Statistical Methods ; The Mann-Whitney test. Student’s
2
t-test, and the -test were used for the statistical analysis 
of the data presented in this thesis. The statistical tables 
of Finney et al., (1963) were also used.
RESULTS
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Table 6
Range of sweat Na levels in the CF patients 
in this investigation
Individual values of Sweat Median
Group Na  ^ Levels ( jnEql and(Range)
VARIABLE 79, 99, 102, 103, 122, 122 (79-154)
ANTIBIOTIC 122, 137, 140, 151, 154
FLUCLOXACILLIN 84,
154
104, 107, 116, 122, 113 (84-154)
NORMAL LEVELS ; - Children < 40 mEql
1
Adults < 80 inEql 1
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SECTION 1 : CLINICAL OBSERVATIONS ON CYSTIC FIBROSIS PATIENTS
Initial Status of the Patients
The patients in this investigation attended Wards 6a, 6h, 
7a and 7b of the Royal Hospital for Sick Children, Glasgow, 
in the period from January, 1978 to June, 1979. They were 
all known CF cases, and no new CF patients were added to those 
selected.
Diagnosis of CF was based on presentation of pulmonary 
symptoms and pancreatic insufficiency, and was confirmed by a 
positive sweat test (Table 6) i.e. a level of Na"*” greater than 
60mEql"^.
As detailed in the Materials and Methods, the patients 
were divided into 2 groups, the Variable Antibiotic group and 
the Flucloxacillin group, at the start of the investigation.
Medical and Socio-economic History
The medical and socio-economic history of the two groups 
of CF patients in this investigation are outlined in Table 7. 
There was no history of consanguinity in any of the families. 
Only one patient (DA) had a CF sibling who was still living. 
His brother (PA) was also one of the patients in the 
investigation.
The history of pregnancy in both groups showed that no 
children were born prematurely, and all the birthweights lay 
between the 10th and 25th centiles.
30
Table 8a
Initial relative underweight in the CP patients of this
inve stigation
Group Severely Moderately Slightly
underweight underweight underweight
VARIABLE
AmiBIOTIC
ER, IL TK, LC, HW, JD, LS AL, EB, JG
EtiUCLGXAC ILLIN LM AT YH, DB
t
Table 8b
Pinal relative underweight in the CP patients of this 
investigation
Group Severely Moderately Slightly
underweight underweight underweight
*
VARIABLE
ANTIBIOTIC
ER TK, LC, HW, JD, LS, 
JG
EB
PLUCLOXACILLIN** LM YH AT, DB
*
lata not available for AL and IL
Lata not available for PA and M
31
Both groups were diagnosed at about the same mean age.
The mean ages at the start of the investigation for both groups 
were also approximately the same (7.3 and 8.3 respect­
ively) . This indicated that any differences in the clinical 
status of the patients in each group was not due to the length 
of therapy alone as this was of the same mean duration in both 
groups.
Each group of patients had been mainly fully immunized 
against polio, diphtheria, tetanus, pertussis and tuberculosis.
The CF patients were drawn from all socio-economic classes 
(Registrar General’s classification). There was no evidence 
to suggest that parental care of CF patients reflected the 
social class to which the patients belonged.
The initial status of the patients was also assessed in 
relation to their relative underweight(weight-deficit corrected 
for height) (Kraemer aj^ . , 1978). The patients were divided 
into 3 categories depending on their degree of underweight 
(Tables 8a,b).It should be noted that those patients with 
respiratory involvement i.e. sputum producers (ER, IL, D S , LM, 
AT) fall into the highly and moderately underweight categories 
while those with little or no pulmonary involvement (no-sputum 
producers) fall into the slightly underweight category.
Clinical Progress 
Effect of Therapy on Weight and Height of CF Patients
Cystio fibrosis, although affecting most of the secretory 
glands in the body, is largely discussed in relation to the
32
Fig. 1(a). Weight of CF patients (boys)
190
eight 170
90
150
Single-Time
Standard
(cross-sectional) 140
130
Repeated-Visit
Standard
(long itud ina l)
■50 -120
-110
100
- 9 040
80
-7 0
-6 0
40
.É ▲
30
-20
-10
A = VARIABLE ANTIBIOTICGROU/® 
• =FLUCL0XACILLIN GROUP
33
Fig. 1(b). Weight of CF patients (girls).
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Fig. 2(a). Height of CF patients (boys).
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Fig. 2(b). Height of CF patients (girls).
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pulmonary and gastrointestinal involvement of the disease.
This combination of pulmonary and gastrointestinal involvement 
frequently results in poor weight gain and short stature.
Weight and height are therefore very useful indicators 
of the clinical progress of the 'CF patient. Of the two 
parameters, weight is regarded as the most important (Sproul 
and Huang, 1964) . They and other investigators (Doershuk jet a 1., 
1964) have shown that weight gain is not determined by the 
severity of the gastrointestinal symptoms as would be expected, 
but by the degree of pulmonary involvement. Thus, if infection 
of the respiratory tract could be well controlled one would 
expect the patients to gain weight normally.
. In this investigation weight and height were considered 
jointly as a measure of improvement in clinical status.
Growth Records of CF Patients
Figs. l(a), 1(b), 2(a), 2(b) show the growth records of 
the patients from birth to the end of the investigation. The 
records were grouped according to the patients* sex. The 
percentile markings are for a normal population.
From figs. 2(a) and 2(b) it can be seen that the heights 
of both boys and girls mainly lay between the 3rd and 25th 
centile. The data between the 75th and 90th centile (boys) 
and the 50th and 75th (girls) were due to single patients 
(EB and ER respectively).
The difference between growth data for CF patients and 
normal children became more apparent when weight rather than 
height was plotted on the charts. The charts also showed
Table 9
Weight gain in CP patients after 18 months
37
Weight (Kg)
Group Patient Initial Pinal Gain
TK 6.5 8o2 1.9
LC 9.2 11.2 2.0
M, 12.5 E/A ——
HW 12.9 14.7 1.8
VARIABLE ^
17.9 e/a
ANTIBIOTIC 22.4 25.6 1.2
m 24.7 25.9 1.2
EB 52.8 54.5 1.7
DS 27.5 28.5 1.0
JG 27.2 26.7 -0.5
MEDIAN 20.2 24.8 1.5
AT 15.2 15.9 2.7
YE 15.5 17.2 1.7
DB 16.9 19.0 2.1
pluc'loxagillin
PA n/a E/A
LM 20.00 18.0 -2.0
DA n/a e/a —
MEDIAN 16.2 17.6 1.9
e/A T= not available. --  = no result
Table 10
Height increase in CP patients after 18 months
3Ô
Height (cm)
Group Patient Initial Pinal Gain
TK 70.0 77.8 7.8
LC 79.5 88.0 8.5
AL 86.2 e/a
HW 97.5 105.4 5.9
VARIABLE n. 118.5 e/a --
ANTIBIOTIC JD 125.1 128.7 5.6
m 157.6 158.8 1.2
EB 147.7 151.5 . 5.8
DB 154.0 158.5 4.5
JG 127.5 155.4 7.9
MEDIAN 120.8 152.1 5.8
AT 96.0 102.5 6.5
YE 102.0 111.0 9.0
PLUCLOXACILLIE DB 107.5 115.0 5.7
PA e/a n/a
LM 123.0 127.0 4.0
BA e/a e/a — —
MEDIAN 104.7 112.0 6.1
e/a = not available ; ----   no result
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that the weight of the girls seemed to he more retarded 
as they approached puberty than the weight of the boys.
After the age of 10 the weight range for girls was < 3rd to 
10th centile. For boys this range was < 3rd to 50th centile. 
Again the data on the 50th centile were due to 1 patient (EB).
There appeared to be no difference between the two investigated
groups regarding the centiles for height and weight of patients 
of comparable age.
Assessment of Weight
The initial and final weight of each patient in the two 
groups was noted and the resulting gain or loss calculated 
(Table 9). The medians of each group were compared using 
the Mann-Whitney Test and found not significant^
Assessment of Height
The initial and final height was noted for each group 
and analysed as for weight (Table 10). The difference of 
the medians was again found to be not significant.
Comparison of CF Weight and Height with Normal Population
The actual weight and height for each patient was 
tabulated (Tables 11, 12) with the expected weight and
height for their chronological age (50th centile). This
was done for these parameters at the beginning and end of 
the investigation. The differences of the medians between 
the groups was analysed and once again, found not significant.
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Pulmonary Changes in CF Patients During the Investigation
The extent of hronolio-pulmonary disease in CF can he 
assessed hy physical and radiological examination. They 
are complementary in determining the pulmonary changes which 
may occur as the disease progresses.
Pulmonary Changes Evident on Physical Examination
(1) Cough : The most prominent and constant symptom of
pulmonary involvement is cough. The cough may, at first, 
he dry and hacking hut with progression of the disease it 
becomes productive and often troublesome at night. Figure 3 
shows the severity of cough in patients of both groups at 
the beginning and end of the investigation. One of the 
patients in the Variable Antibiotic group who had no cough 
initially developed a slight cough during the 18 months (HW). 
His cough, however, was non-productive. In the Flucloxacillin 
group, DA who had a non-productive cough initially, responded 
to treatment sufficiently that coughing ceased. LM, although 
having a severe cough throughout, ceased night coughing shortly 
after the investigation started.
(2) Sputum : Severity of sputum production was assessed 
by the frequency of sputum produced daily and the ease of 
expectoration i.e. produced during coughing or only by 
physiotherapy. Figure 4 illustrates the amounts of sputum 
expectorated by the CF patients and shows that there was ko 
change during the investigation.
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(3) Digital Clubbing : Digital clubbing is one of the
physical manifestation! of pulmonary changes. It arises 
from the enlargement of the bronchial artery and the systemic 
vascular supply to the lungs. Figure 5 shows the degree of 
clubbing for both groups. In the Variable Antibiotic group 
DS had mild clubbing at the start of the investigation, but 
this had become moderately severe after 18 months. This 
patient also had severe cough and copious sputum production. 
In the Flucloxacillin group, YH developed very mild clubbing ■ 
a first sign of pulmonary Involvement. LM had progressed 
from mild clubbing to moderately severe clubbing during the 
investigation.
Pulmonary Changes Evident on Radiological Examination
The radiographic manifestations of pulmonary disease in 
CF are often seemingly out of proportion to the clinical 
status of the patient. The earliest radiological signs of 
disease are usually bronchial thickening and irregular areas 
of hyperinflation. In advanced disease, segmental or lobar 
atelectasis, cyst formation, extensive bronchiectasis, 
retained secretions, and extensive infiltrates are seen. 
Appendices 1 and 2 summarize the severity of radiological 
and physical findings in both groups of patients at the start 
and end of the investigation. No overall improvement in 
the radiological findings was observed. EB showed slight 
deterioration and LM marked deterioration.
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Table 13
Hospital admission rate of CP patients
Group Patient
Hospital Admissions 
18 months pre-trial 18 months during trial
TK 1 1
LC 0 0
AL 1 —
HW 1 0
VARIABLE n. 0 0
AETIBIOTIC JH 1 0
m 0 0
EB 1 0
BS 4 1
JG 0 0
m m  RATE 0.9 0.2
AT 4 1
YB 1 1
DB 0 0
PLÜGLOXACILLIH PA 0 0
IM 2 3
DA 0 0
m m  RATE 1.1 0.8
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Hospitalization for Acute Exacerbation
The number of times a CF patient is admitted to hospital 
can, in some cases, be dependent on the physician-in-charge. 
However, those involved in treating CF agree with Wood ejt a l . , 
(1976) that in order to avoid unnecessary exposure to infection 
patients should have as little contact as possible with the 
hospital environment.
The number of hospital admissions therefore became 
another parameter which could be employed in assessing 
clinical progress (Table 13). A fall in the rate of hospital 
admissions would have a two-fold effect. Firstly the cost to 
the health service. It is less expensive to treat a patient 
at home than in hospital. Secondly, the benefit to the patient 
A child is usually far happier in an environment it knows.
There is therefore a psychological advantage in keeping the 
child with its parents and relying on them for administration 
of therapy.
In Table 13 those patients who had little or no cough and 
no sputum (no-sputum producers) were either admitted once or 
not at all during the 18 months pre-investigation (i.e. TK, LC, 
AL, HW, JD, JG, YH, DB, DA). Of these patients TK and YH 
were admitted during the investigation. TK had a rectal 
prolapse which required ' ., ■ admission in the day-bed area
for treatment by alcohol injection. YH had an exacerbation 
which required an l8 day admission.
The remaining patients in both groups are those who had 
both cough and sputum expectoration (sputum producers). Of
these patients IL, ER and PA had no admissions either pre or
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during the investigation. EB was admitted once pre­
investigation hut not during the investigation.
However, probably the most significant difference can be 
seen in the admission rate for DS and AT. In both instances 
this dropped from 4 admissions pre-investigation to only one 
during the investigation. In the case of DS this was merely 
for 4 days observation. AT did require intravenous amino­
glycoside therapy for an exacerbation caused by Fr .mirabilis 
and P . aeruginosa.
LM was the only patient who had more hospital admissions 
during than before the investigation. The two admissions pre­
investigation were during the first 5 months of the 18 month 
period and were both of 14 days duration. The first of the 
3 admissions during the investigation occurred 19 months later. 
This was of 7 days duration and was followed after one month 
by an acute exacerbation which required hospitalization for 
36 days. The third admission occurred 3 months later and was 
for observation after haemoptysis was detected. This was of 
3 days duration. This patient died 6 weeks later.
The decrease in admission rate during the investigation 
was not significant (p> 0.05, Students' t-test) either for the 
Variable Antibiotic group or the Flucloxacillin group(p> 0.05).
SECTION II : BACTERIOLOGICAL OBSERVATIONS
Records of Isolations of Pathogens
Results of Nose and Throat Swabs and Sputum Specimens
The nose and throat swabs and sputum specimens were obtained
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Table 14
■ Frequency of isolations of pathogens from specimens 
in the Variable Antibiotic and Flucloxacillin groups
Organism
NOo of Isolates 
No • of Specimens
i%)
VARIABLE ANTIBIOTIC 
GROUP
EIiTJOLOXACILIiIN
GEODP
8. aureus 61/490 (12) 59/175 (34)
H. influenzae 33/490 (7) 19/175 (11)
P. aeruginosa 105/490 (21) 9/175 (5) **
Ho parahaemolyticuB 26/490 (5) 2/175 (1) *
H. parainfluenzae 7/490 (1) 3/175 (2)
St. faecalis 23/490 (5) 1/175 (1) *
Pr. mirabilis 5/490 (1) 19/175 (11) **
E. coli 13/490 (3) 6/115 (3)
* = denotes significant difference (p < 0.05)
** = denotes highly significant difference (p <  O.OOl)
Table 15
Bacteriological analysis of the sets of specimens 
from the OF patients.
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Nature of
Number (%) of Specimens Yielding Pathogenic, 
Bacteria
Specimen VARIABLE ANTIBIOTIC 
GROUP
II,UOLOXACTTrTiTO
GEOOP
SP HSP SP NSP
NOSE SWAB 3/84. (4) 32/122 (26) 4/27 (15) 14/43 (33)
THROAT SWAB 32/81 (40) 36/122 (30) 10/25 (40) 12/43 (28)
SPDTÜM 74/81 (91)** — — 37/37 (100)** ---
SP = Sputum producers; NSP = No-sputum producers
=s No specimen obtained
denotes highly significant difference (p <  O.OOl) 
Sputum specimens compared with the other specimens 
of SP and .NSP within the same group.
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as described in the Materials and Methods.
During the 18 months of the investigation a total of 
490 specimens were taken from the Variable Antibiotic group 
and 175 specimens from the Flucloxacillin group. Table 14 
shows the frequency of the isolations of each organism from 
the 2 groups.
The data showed that P . aeruginosa, H. parahaemolyticus 
and St.faecalis were isolated at a higher frequency from the 
Variable Antibiotic group than the Flucloxacillin group.
This difference was significant for H. parahaemolyticus and 
St. faecalis (p < 0.05) and highly significant for P. aeruginosa 
(p < O.OOl). P r . mirabilis was the only organism which was 
isolated at a greater frequency from the Flucloxacillin group 
than the Variable Antibiotic group (p < 0.001).
There was no significant difference between the groups for 
the isolation of the other organisms (p > 0.05).
Sputum is, of course, the specimen of choice from CF 
patients. However, in some patients, especially those under 
the age of 5 years, it is very difficult to obtain sputum 
without using suction. It was therefore thought that in these 
patients, nose and throat swabs would be an acceptable 
substitute for sputum. Nose and throat swabs were also taken 
from patients who could produce sputum.
Thus, at every visit, 2 specimens were obtained from 
patients unable to produce sputum and 3 from those who could 
produce sputum. A comparison of the number of these specimens 
which yielded pathogens was made for each group (Table 15).-
Table 16
Isolation of pathogenic bacteria from CP patients 
at the beginning and end of the trial
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Number (%) of Patients with Organism
Organism
VARIABLE ANTIBIOTIG 
GROUP
Initial Pinal
PLUOLOXACILLIN 
GROUP______
Initial Pinal
Non-CP
Patients
8. aureus
H. influenzae
Po aeruginosa
Miscellaneous
Commensals
Only
5/10 (50)*» 7/10(70)** 4/6(67)* 3/6(50) 32/200(16)**
3/10 (30) 4/10(40)* 4/6(6?)*' 1/6(17) 15/200(8)*
2/10 (20)** 4/10(40)** 1/6(17) 2/6(33)** 1/200(0.5)**
3/10 (30) 7/10(70) 5/6(50) 1/6(17) 76/200(38)
4/10 (40) 2/10(20) 0/6(0) 1/6(17) 94/200(47)
—
# #
denotes significant difference (p <0,05) Variable Antibiotic 
Group vs non-CP patients.
denotes highly significant difference (p <  O.OOl) »>
= denotes significant difference (p <0.05) Plucloxaoillin 
Group vs non-CP patients.
= denotes highly significant difference (p < O.OOl) "
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Here each of the 2 groups was suh-divlded into sputum producers 
and no-sputum producers. Consequently, the sputum specimens 
were taken as the base for comparison.
Analysis for the Variable Antibiotic group showed that 
the number of sputum specimens which yielded pathogens was 
significantly greater than the number of nose and throat swabs 
which yielded pathogens (p < O.OOl). This result was irrespective 
of whether the swabs had been taken from sputum producers or no­
sputum producers.
The same highly significant difference was obtained for 
the Flucloxacillin group.
In order to determine the effect of the 2 methods of therapy 
on the bacterial flora of the groups, the pathogenic bacteria 
isolated at the beginning and end of the investigation from CF 
patients were compared (Table 16) . There was no significant 
difference in the number of patients in each of the groups 
whose specimens yielded any of the pathogens at the beginning 
of the investigation from those at the end of the investigation 
(p > 0.1).
However, when these results were compared with analogous 
specimens taken from non-CF patients, the differences became 
significant.
There was a highly significant difference in the isolation 
of S. aureus and P. aeruginosa from the OF patients in the 
Variable Antibiotic group compared to those of the non-CF 
patients (p < O.OOl). This difference applied to both initial 
and final isolations of pathogens. S. aureus was isolated
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from 50 per cent of CF patients initially and 70 per cent 
finally. For non-CF patients the overall figure was 16 per 
cent. The corresponding results for P. aeruginosa was 20 
per cent and 40 per cent from CF patients and 0.5 per cent 
from non-CF patients. The P. aeruginosa isolated from the 
non-CF patients was grown from a sputum specimen from a patient 
recovering from cardiac surgery.
There was no significant difference initially for 
H. influenzae (p > O.l) hut at the end of the Investigation this 
organism was isolated from 40 per cent of the CF patients in 
this group compared to only 8 per cent of non-CF patients.
Here the difference was highly significant (p < O.Ol).
In the Flucloxacillin group the number of patients with 
S . aureus and H. influenzae fell during the period of the 
investigation from 67 per cent to 50 per cent, and 67 .per cent 
to 17 per cent respectively. Th£se dif f erences^We-e- significant 
(p < O.Ol) at the beginning of the investigation. However, 
at the end of the Investigation the . -
(p > O.l).
This result suggests that the treatment for the Flucloxacillin 
group was effective for both S. aureus and H . influenzae,
The isolation of P. aeruginosa showed a different trend.
At the beginning of the investigation only one patient in 
this group yielded this organism. When compared to the non- 
CF patients the difference was not significant (p > 0.05).
The difference between non-CF patients and those of the 
Flucloxacillin group was significant however at the end of
the investigation (p < O.OOl).
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Table I7
Isolation rates of pathogenic bacteria during the 
inve st igat ion.
Number {%) of patients with organism
ORGANISM Sputum Producers No-Sputum Producers
S. aureus 6/7 (86) 6/9 (67)
Ho influenzae 5/7 (71) 6/9 (67)
P. aeruginosa 6/7 (86) 0/9 (0) *
Miscellaneous 7/7 (100) 8/9 (89)
Commensal s 0/7 (0) 3/9 (33)
Only
* = denotes highly significant difference (p <  O.Ol)
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Table 18
Isolation rates of pathogenic bacteria during the 
investigation
Number (5^ ) of Patients with organism
Organism VARIABIE ANTIBIOTIC 
GROUP
iliUCLOXACILLIH
GRoro
S, aureus 8/10 (80) 4/6 (67)
H. influenzae 6/10 (60) 5/6 (85)
P. aeruginosa 4/10 (40) 2/6 (33)
Miscellaneous lo/io (100) 5/6 (83)*
Commensals
Only
2/LO (20) 1/6 (17)
* = denotes significant difference (p < 0.05)
r— I
r4
O
P4'-O'
4-
 cti
O Oo
om.
O:o o
maO
59
E p i d e m i o l o g y  of CF P a t i e n t s
Figure 6 shows the isolation rates of pathogenic bacteria 
from all CF patients and non-CF patients. The figure depicts 
the percentage and number of patients who, during the l8 month 
period of the investigation harboured the bacteria in question 
in the respiratory tract at one or more examinations.
The results show that of the three major pathogens associated 
with OF S. aureus was the predominating organism (75 per cent) 
followed by H. influenzae (69 per cent) and P. aeruginosa 
(38 per cent). The pattern is the same for non-CF patients 
but reflect a much lower isolation rate i.e. S. aureus 
(l6 per cent), H. influenzae (8 per cent), and P. aeruginosa 
(0,5 per cent). The differences in the isolation rates 
between the 2 categories of patients are highly significant
(p < 0 .001).
In order to determine whether there were any significant 
differences in the isolation rates of the major pathogens 
within the CF patients, the data were arranged such that a 
comparison could be made between sputum producers and no­
sputum producers (Table 17) and patients in the Variable 
Antibiotic and Flucloxacillin groups (Table 18) .
The ranking of predominant organisms was the same for 
the Variable Antibiotic group as that given in Figure 5 i.e.
S. aureus (80 per cent), H. influenzae (60 per cent), and 
P. aeruginosa (4-0 per cent). This order changed somewhat 
for the Flucloxacillin group. Here H. influenzae was the 
predominating organism (83 per cent) followed by S. aureus
Table 19
Number of Isolations of each pathogen from the 
respiratory tract of OF patients.
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Organism
RESPIRATORY TRACT SITE
Lower 
Respiratory 
Tract Only
Throat
Only
Nose
Only Combination Total
S, aureus 5.9 15 26 17 97
E. influenzae 21 5 16 3 43
P. aeruginosa ' 60 4 0 . 25 89
Miscellaneous 47 50 12 10 119
Total 167 72 54 55 348
61
(67 per cent) and P. aeruginosa (33 per cent). The differences 
were not significant between the 2 groups for the major 
pathogens (p > 0.05). However, for the miscellaneous 
organisms, the differences were significant (p < 0.05).
The isolation rates in Table 17 show that S . aureus 
and P. aeruginosa were isolated with equal frequency (86 per 
cent) followed by H. influenzae (71 per cent) in sputum 
producers. S. aureus and H. influenzae were isolated with 
equal frequency (67 per cent) from no-sputum producers.
P. aeruginosa was not isolated at all from these patients.
This suggests that P. aeruginosa tends to be localized in those 
CF patients with advanced pulmonary infection. Indeed the 
only significant difference was seen in the isolation rates 
of P. aeruginosa in sputum producers and no-sputum producers. 
Here the difference was highly significant (p < 0.01).
Location of Pathogenic Bacteria in the Respiratory Tract
Table 19 shows the number of isolations of each pathogen 
from the different sites of the respiratory tract. The upper 
respiratory tract encompasses the nose and throat and the lower 
respiratory tract consists of the trachea, bronchi, bronchioles, 
and the alveoli. Sputum is obtained from the bronchi. All 
three of the major pathogens were isolated mainly from the 
lower respiratory tract. The miscellaneous organisms seemed 
fairly evenly distributed between the lower respiratory tract 
and throat only, being rarely isolated from the nose.
The most commonly isolated organism from, the nose only was
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S . aureus. This was not unexpected since the nares and 
skin are the commonest source of this organism in humans.
Analysis showed that the isolates for S . aureus were 
significantly greater from the lower respiratory tract than 
the throat (p < O.OOl). There was no significant difference 
when the number of isolations was compared for the lower 
respiratory tract and nose only (p > 0.05).
Similarly H. influenzae was also isolated in larger 
numbers from the lower respiratory tract closely followed 
by nose only. The differences between the lower respiratory 
tract and throat an{i nose and throat are significant (p < 0.01)
The distribution of P. aeruginosa was completely different 
This organism was almost exclusively isolated from the lower 
respiratory tract. In the cases where this organism was 
isolated from the throat only, the patient, PA, did produce 
sputum but not on every occasion. Therefore, this was a 
contamination rather than actual colonization. The combined 
isolations referred to lower respiratory tract and throat only 
for this organism. On no occasion was P. aeruginosa isolated 
from the nose. The differences here are highly significant
(p < 0.001).
Analysis of the total isolations of all organisms at 
each site show that the differences between lower respiratory 
tract isolations and those of other respiratory tract sites 
were significant (lower respiratory tract vs. throat, p < 0.05; 
lower respiratory tract vs. nose, p < 0,01), whereas comparing
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Table 20
Isolation of pathogenic bacteria from nose 
swabs of Sputum producers and No-sputum producers.
Number (%) of Nose Cultures which yielded bacteria
Organism Sputum Producers No-sputum Producers
S. aureus 5/108 (5) 34/165 (21)
H. influenzae 1/108 (1) 17/165 (10) *
P. aeruginosa 0/108 (O) 0/165 (0)
Miscellaneous 1/108 (1) 12/165 (7) *
Commensals
Only
101/108 (94) 129/165 (78) **
* = denotes significant difference (p <Q.05)
** = denotes highly significant difference (p <  O.OOl)
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nose and throat i.e. upper respiratory tract isolations were 
not significant (p > 0.05).
Thus as would he expected in CF patients, the lungs are 
the main source of potential pathogens in this condition.
During the period of the trial, as each patient record 
was compiled, a striking difference emerged between sputum 
producers and no-sputum producers. This was irrespective of 
which of the 2 groups they belonged to. The number of nose 
swabs which were positive for pathogens in no-sputum producers 
was greater than those of sputum producers. These data were 
therefore included in a separate table to determine if this 
difference was significant (Table 20).
Again by far the commonest organism in the nose cultures 
of no-sputum producers was S. aureus (21 per cent of all cultures) 
With the exception of P. aeruginosa (which, as previously stated, 
was not isolated from the nose) the percentage of nose cultures 
from no-sputum producers which yielded bacteria was significantly 
greater than cultures from sputum producers (p .< 0.05), For 
S . aureus this difference was highly significant (p < 0.001).
Since the nose cultures of no-sputum producers yielded 
a significantly greater number of pathogenic bacteria than those 
of sputum producers, one might expect the nose cultures of 
sputum producers to have a higher percentage of cultures which 
yielded commensals. This was indeed the case, for 94 per 
cent of nose cultures from sputum producers had commensals, 
compared to 78 per cent of no-sputum producers. This difference 
was highly significant (p < O.OOl).
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Table 21
Antibiotic sensitivities of the main pathogens in CF compared
with those of the same bacterial species isolated from non-CF patients.
Number (%) of Organisms Sensitive Value of
Antibiotic CF Patients Non-CF Patients ? 2 ^  .X -test
Staphylococcus aureus
Benzylpenicillin 8/120 (?) 0/$2 (O) >0.1
Ampicillin 8/l20 (?) 0/$2 (O) >0.1
+ 14 other antibiotics showed no significant difference (see Appendix 5) 
Haemophilus influenzae
Ampicillin 51/52' (98) 9/l5 (60) <0.001
+ 15 other antibiotics showed no significant difference (see Appendix 3) 
Pseudomonas aeruginosa
Carbenioillin 4/66 (6) 2/II (18) >0.1
Tetracycline 31/66 (47) l/ll (9) <0.05
Gentamicin 66/66 (lOO) S/ll (73) <  0.001
+ 10 other antibiotics showed no significant difference (see Appendix 5)
Pseudomonas aeruginosa (Rough vs Mucoid strain)*
Cotrimoxazole 0/66 (O) 9/48 (19) <  0.001
Sulphonamide 4/66 (6) II/48 (23) <  0.01
Ampicillin O/66 (O) 6/48 (13) <  0.01
+ 10 other antibiotics showed no significant difference (see Appendix 3)
* = The number (%) of organisms sensitive refer to rough and mucoid strains 
both from CF patients.
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Table 22
Antibiotic sensitivities of pathogens isolated from CF patients 
compared with those of the same bacterial species from non-CF 
patients.
Antibiotic
Number (%) of Organisms Sensitive 
CF Patients Non-CF Patients
Value of 
p in 
X^-test
Haemophilus parainfluenzae
Benzylpenic illin 8/10 (80) 3/8 (38) < 0.05
Cephradine 3/10 (30) 7/8 (88) < 0.05
+ 14 other antibiotics showed no significant difference (see Appendix 4)
Escherichia coli
Ampicillin 16/19 (84) 78/153 (59) < 0.05
Carbenioillin 17/19 (90) 8O/133 (60) <  0.05
Tetracycline 19/19 (100) 109/133 (82) <  0.05
Cephradine 16/19 (84) 130/133 (98) <0.01
+ 9 other antibiotics showed no significant difference (see Appendix 5)
Proteus mirabilis
Cotrimoxazole 16/24 (67) 30/31 (97) <  0.01
Sulphonamide 10/24 (42) 30/31 (97) <  0.001
Ampicillin 24/24 (100) 26/31 (84) <  0.05
Carbenioillin 24/24 (100) 26/31 (84) < 0.05
Tetracycline I8/24 (75) 1/31 (3) <  0,001
Cephradine 16/24 (67) 30/31 (97) <0^01
+ 7 other antibiotics showed no significant difference (see Appendix 5)
Streptococcus faecalis
C otrimoxazole 21/24 (88) 0/52 (0) <  0.001
Sulphonamide 22/24 (92) 0/52 (0) < 0.001
Carbenioillin 9/24 (38) 51/52 (98) <0.001
Tetracycline 24/24 (100) 30/52 (58) <  0.001
Cephradine 24/24 (100) 25/52 (48) <  0.001
+ 8 other antibiotics showed no significant difference (see Appendix 5),
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Antibiotic Sensitivities
The antibiotic sensitivities of the pathogens isolated 
from the CF patients were determined using the disk diffusion 
technique as outlined in the Materials and Methods. The 
antibiotic sensitivities were compared to those of non-CF 
patients (Appendices 3, 4, 5).
Tables 21 and 22 summarise the data in the appendices.
These tables show the antibiotic sensitivities of the pathogens, 
which were significantly different, from CF and non-CF patients 
as detailed below.
The differences in the numbers of isolates of S. aureus 
from CF and non-CF patients sensitive to the antibiotics tested 
were not significant ( p > 0.05). H. influenzae isolated 
from CF patients was significantly more sensitive to ampicillin 
than the same organism isolated from non-CF patients (p < O.OOl).
A two-way comparison was made for P. aeruginosa viz. CF 
(rough strain) vs. non-CF patients and rough strain vs. mucoid 
strain (both from CF patients) (Table 21) .
The only antibiotics which showed a significant difference 
between CF and non-CF patients were tetracycline and gentamicin.
Of the isolates from CF patients 47 per cent were sensitive to 
tetracycline compared to 9 per cent from non-CF patients (p < 0.05) 
The corresponding figures for gentamicin were 100 per cent and 
73 per cent respectively (p < 0.001). However, when the 
antibiotic sensitivities of the rough and mucoid strains of 
P. aeruginosa from CF patients were compared the results were 
noteworthy.
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No significant differences emerged for the antibiotics 
which were largely specific for gram-negative organisms i.e. 
carbenioillin, gentamicin, tobramycin, neomycin and colistin.
The most striking differences were seen in the sensitivity of 
the mucoid strains to cotrimoxazole, sulphonamide, and 
ampicillin. None of the rough strains were sensitive to 
cotrimoxazole compared to 19 per cent of the mucoid strains.
Only 6 per cent of the rough strains were sensitive to 
sulphonamide whereas 23 per cent of the mucoid strains were 
sensitive. Again none of the rough strains were sensitive 
to ampicillin compared to 13 per cent of mucoid strains.
These differences were highly significant (p < O.Ol).
P. aeruginosa can, in some instances, be sensitive to 
cotrimoxazole and sulphonamide. It is usually resistant to 
penicillins with the exception of carbenioillin which is a 
synthetic penicillin specific for gram-negative organisms.
Thus, it would appear that the mucoid strain of P. aeruginosa 
is, at least in vitro, more sensitive to antibiotics than the 
rough strain.
No significant differences were apparent between CF and 
non-CF patients for H. parahaemolyticus. Of the isolates of 
H. parainfluenzae 80 per cent from CF patients were sensitive 
to benzylpenicillin compared to only 38 per cent of non-CF 
patients. This difference was significant (p < 0.05). However, 
the isolates of H. parainfluenzae from CF patients were less 
sensitive to cephradine (30 per cent) than those from non-CF 
patients (88 per cent). This difference was also significant 
(p < 0.05).
E . coli from CF patients were significantly more sensitive 
to ampicillin, carhenicillin, and tetracycline than those from 
non-CF patients (p < 0.05). However, this organism was
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Table 23
Distribution of Antibiograms and percentage of patients
harbouring Staphyloooocus aureus
ANTLBIOGRAM
Percentage of Strains
VARIABLE FLUGLOXA-
ANTIBIOTIG 0ILLIN 
GROUP GROUP
(61 strains) (39 strains)
Percentage of Patients 
harbouring strains
VARIABLE FLUCLOXA-
ANTIBIOTIG OILLIN 
GROUP GROUP
(lO Patients) (6 Patients)
P PN 77 88 80 67
Sensitive 10 2 20 17
P Pn E 7 7 10 17
P Pn E N 2 0 10 0
P Pn N K 2 0 10 0
P Pn E N K 2 0 10 0
P Pn Te E 0 2 6 17
For explanation of abbreviations see Table 2 (page 19 ).
Table 24
Distribution of Antibiograms and percentage of patients 
harbouring Haemophilus influenzae
ANTIBIOGRAMS
VARIABLE FLUCLOXA- 
ANTIBIOTIC CILLIN 
GROUP GROUP
(31 strains)(21 strains)
VARIABLE
ANTIBIOTIC
GROUP
(10 Patients)
FLUCLOXA­
CILLIN
GROUP
(6 Patients)
P Ob Ce My 23 0 30 0
Ob Ce My 19 29 50 33
Ob Ce My Fd 16 24 30 17
P Ob Ce My Fd 13 0 20 0
Ob jyfer Fd 10 19 30 17
P Ob My Fd 0 10 0 17
Ob %r 0 10 0 17
For explanation of abbreviations see Table 2 (pagel9 ).
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Table 25
Distribution of Antibiograms and percentage of patients
harbouring Pseudomonas aeruginosa (Rough strain)
Percentage of Strains Percentage of Patients 
harbouring strains
ANTIBIOGRAM VARIABLE
a n t i b i o t i c
GROUP
(58strains)
FLUCLOXA­
CILLIN
GROUP
(Sstrains)
VARIABLE FLUCLOXA- 
ANTIBIOTIC CILLIN 
GROUP GROUP 
(10 Patients)(6 Patients)
Sxt Sf pi Py Te Kz Or Ce K 36 38 30 17
Sxt Sf Pn Py Kz Cr Ce K 26 50 40 17
Sxt Sf Pn Py Te Kz Cr Ce N K 12 0 20 0
Sxt Sf Pn Py Kz Cr Ce Ct K 7 0 20 0
Sxt Pn Py Kz Cr C© K 7 0 10 0
Sxt Sf Pn Kz Cr Ce K 5 0 30 0
Sxt Sf Pn Py Te Kz Cr Ce 3 13 20 17
For explanation of abbreviations see Table 2 (page 19 ).
Table 26
Distribution of Antibiograms and percentage of patients 
harbouring Pseudomonas aeruginosa (Mucoid strain)
Percentage of Strains Percentage of Patients 
harbouring strains
. ANTIBIOGRAM
VARIABLE
ANTIBIOTIC
GROUP
FLUCLOXA­
CILLIN
GROUP
VARIABLE FLUCLOXA- 
ANTIBIOTIC CILLIN 
GROUP GROUP
(47strains) (istrain) (lOPatients) (6Patients)
Sxt Sf Pn Py Te Kz Cr Oe K 45 0 20 0
Sxt Sf Pn Py Kz Cr Ce K 17 0 20 0
Sxt Sf Pn Py Te Kz Cr Ce 6 100 10 17
Sxt Sf Pn Py Te Kz Cr Ce N K 6 0 10 0
Kz Cr Ce 6 0 10 0
Pn Py Kz Cr Ce K 6 0 10 0
Kz Ce 4 0 10 0
For explanation of abbreviations see Table 2 (page 19 ).
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Table 27
Distribution of Antibiograms and percentage of patients
harbouring Haemophilus parainfluenzae
Percentage of Strains Percentage of Patients
ANTIBIOGEAM VARIABLE
ANTIBIOTIC
GROUP
FLUCLOXA­
CILLIN
GROUP
VARIABLE
ANTIBIOTIC
GROUP
FLUCLOXA­
CILLIN
GROUP
(7 strains) (5 strains) (lO Patients) (6 Patients)
Ob Ce My Pd 29 0 20 0
P Ob Ce My Pd 29 0 20 0
Sf Ob Ce My 14 0 10 0
Ob Ce My  ^14 33 10 17
Ob My Pd 14 67 10 33
Per explanation of abbreviations see Table 2 (page 19 ).
Table 28
Distribution of Antibiograms and percentage of patients 
harbouring Streptococcus faecalis
Percentage of Strains Percentage of Patients 
harbouring strains
ANTIBIOCRAM VARIABLE
A n t i b i o t i c
GROUP
FLUCLOXA­
CILLIN
GROUP
VARIABLE
ANTIBIOTIC
GROUP
FLUCLOXA­
CILLIN
GROUP
(23strains) (istrain) (lOPatients) (6Patients)
Py Ct 43 100 50 17
Ct 30 0 50 0
Sxt Py Ct 9 0 10 0
Sxt Ct 4 0 10 0
Por explanation of abbreviations see Table 2 (pag■e 19 ).
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Table 29
Distribution of Antibiograms and percentage of patients
harbouring Proteus mirabilis
Percentage of Strains Percentage of Patients 
harbouring strains
ANTIBIOGRAM
VARIABLE
ANTIBIOTIC
GROUP
(5 strains)
FLUCLOXA- VARIABLE FLUCLOXA­
CILLIN ANTIBIOTIC CILLIN 
GROUP GROUP GROUP 
(19 strains) (lO Patients) (6 Patients)
Sf Ct 40 26 10 33
Sxt Ct 20 5 10 17
Ct 0 26 0 17
Sxt Sf Ce Ct 0 11 0 17
Sxt Sf Te Ce Ct 0 16 0 17
Por explanation of abbreviations see Table 2 (page 19).
Table 30
Distribution of Antibiograms and percentage of patients 
harbouring Escherichia coli
Percentage of Strains Percentage of Patients 
harbouring strains
ANTIBIOGRAM VARIABLE
ANTIBIOTIC
GROUP.
FLUCLOXA­
CILLIN
GROUP
VARIABLE
ANTIBIOTIC
GROUP
FLUCLOXA­
CILLIN
GROUP
(13 strains) (6 strains) (10 Patients) (6 Patients)
Sensitive 46 100 20 17
Ce 15 0 10 0
Sf Pn Py 8 0 10 0
Sf Pn 8 0 10 0
Pn Py K 8 0 10 0
Por explanation of abbreviations see Table 2 (page 19).
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significantly more sensitive to cephradine when isolated from 
non-CF patients (98 per cent) than CF patients (84 per cent)
(p < 0.01).
The isolates of F r . mirabilis from CF patients were more 
sensitive to ampicillin, carbenioillin, and tetracycline 
(p < 0.05). Those from non-CF patients were more sensitive 
to cotrimoxazole, sulphonamide, and cephradine (p < 0.01).
The comparative resistance of CF isolates to cotrimoxazole, 
sulphonamide, and cephradine were due to one patient (AT).
This patient had chronic carriage of P r . mirabilis. His 
particular strain of P r . mirabilis rapidly became resistant 
to these antibiotics. The resistance was not lost during the 
period of the trial.
St. faecalis from CF patients were significantly more 
sensitive to cotrimoxazole, sulphonamide, and cephradine (p < 0.001 
whereas those from non-CF patients were significantly more 
sensitive to carbenicillin (p < 0.001).
Antibiograms of Pathogenic Bacteria
Antibiograms of every pathogen were compiled for each group 
of CF patients. This made the detection of specific resistances 
easier, especially if they were frequently found in one group 
of patients or one particular patient within that group.
The most frequently found antibiograms for the pathogens 
are listed in Tables 23, 24, 25, 26, 27, 28, 29 and 30.
Statistical analysis showed only Table 27 with a significant 
difference. The number of strains of the Flucloxacillin group 
with the ’’sensitive” antibiogram was significantly greater than
those in the Variable Antibiotic group (p < 0.05).
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Table 31
Number of Antibiograms for each pathogen in the 
two groups of CP patients.
Number of Antibiograms in each group per total 
number of Antibiograms
Organism VARIABLE ANTIBIOTIG 
GROUP
H.ÏÏ0I,0XACI1LIH
GROUP
S. aureus 7/9 5/9
H. influenzae 11/15 8/15
P. aeruginosa 9/15 3/15 *
H. parahaemolyticus 3/5 1/5
H. parainfluenzae 5/5 2/5
St. faecalis 7/7 1/7 *
P. mirabilis 4/10 B/lO
E, coli 7/7 1/7
* = denotes significant difference (p <  0.05)
Fig. 7. Phage-type of S. aureus isolated from
CF patients for which^hage-typing results 
were available (60 per cent of S. aureus) .
NT = Not typable; w = weak reaction;
+ = some additional reactions also present;
N = nose swab; T = throat swab; S = sputum; 
* or ®  specimens taken on same day 
Phage-types in full JGl = 42E/47/54/7 5/81* 
IL3 and IL4 = 6/47/54/75/88/81'*';
ATI = 47/53/54/75/77/81;
TKl = 29V 42E V 75V 81''.
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The total numher of antibiograms in each group were compared 
for significant differences (Table 31). The Variable Antibiotic 
group had significantly more antibiograms for P. aeruginosa.
St. faecalis, and E . coli than the Flucloxacillin group (p < 0.05)
Although S t . faecalis may appear to have greater antibiotic 
variation in patients in the Variable Antibiotic group it should 
be noted that this, organism was almost uniquely isolated from 
this group. Only specimens from YH of the Flucloxacillin group 
yielded St. faecalis and on only one occasion.
The same can be said of P . aeruginosa. This organism 
was only isolated on nine occasions from the Flucloxacillin 
group and from 2 patients (PA, AT), whereas the 105 isolates of 
P. aeruginosa from the Variable Antibiotic group were from A 
patients (pg, e R, EB, IE).
Phage Typing of Staphylococci 
Phage Types of S. aureus from CF and non-CF Patients
In order to determine whether a patient was colonized with 
the same strain of S. aureus at all sites of the respiratory 
tract the S. aureus were phage-typed as well as being tested 
for antibiotic sensitivity. Approximately 60 per cent of all 
S. aureus Isolated were phage-typed.
Figure 7 shows both the phage-type and sequence of 
isolation of S. aureus from the 2 groups of patients under 
investigation during the 18 months of the trial. The organism, 
itself, was largely isolated from sputum and nose swabs.
The phage-type of S. aureus, isolated from more than one
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site of the respiratory tract from specimens taken on the 
same day, from the same individual were usually identical.
Of the specimens whose S. aureus were phage-typed only 4-4 
per cent yielded S. aureus of different phage-types. DS 
was the only patient whose specimens taken on the same day 
yielded S. aureus from all three sites i.e. nose, throat, 
and lower respiratory tract. The antibiotic sensitivity 
pattern for all three organisms was identical but the phage- 
types were different, although all belonged to phage-group III,
There was no evidence to suggest that there was a link 
between antibiotic sensitivity and phage-type. The only 
exception to this was patient XL. On 2 occasions S. aureus 
grown from his sputum specimens gave phage reactions in group III 
(6/47/ 54/75/77/88/81^). This particular phage group has been 
shown to be common in S . aureus which carry the plasmid for 
resistance to kanamycin and neomycin (Lacey, 1971a). This is 
a linked resistance. The S. aureus from IL were resistant to 
these antibiotics.
It can also be seen from figure 7 that most of the patients 
were colonized by S. aureus belonging to one group e.g. LC and 
LM:- both with non-typable phage ; EB:- phage of the 8O/8I 
complex ; E R : - group III and miscellaneous; AT:-group I;
DA:- 83A and non-typable; DB : - group II especially the 55/71 
complex.
This pattern of phage-typing was compared to that of non-CF 
patients who were also chronic carriers of S . aureus. The best 
example of this from the hospital records were patients in
Ward 1C (Renal Unit). These patients were the only ones who,
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like CF patients, had regular specimens taken from the upper 
respiratory tract. Only 3 of these patients had chronic carriage 
of S. aureus (Figure 8). These 3 patients each appear to be 
colonized with 5. aureus of predominantly one group.
Patient 1: - non-typable; patient 2 : - group II; and patient 
3:- group I. This is similar to CF patients.
The phage-types for both the CF patients and non-CF patients 
(chronic carriage) were arranged into their phage groups and 
compared with those of 100 randomly selected non-CF patients 
who did not have a chronic respiratory infection. (Table 32).
Non-typable strains of S. aureus were the most frequently 
isolated from CF patients (33 per cent of the specimens). This is 
a not uncommon finding in patients receiving prophylaxis. Non- 
typable strains were also the most frequently isolated from 
the non-CF patients (chronic carriage). These patients would 
also be receiving prophylaxis.
When all three categories of patients were compared the 
following emerges ;
There was no significant difference in the number of 
S. aureus belonging to each phage-group between CF and non-CF 
patients (chronic carriage) (p > 0.05 in all'cases). However, 
when the CF patients and non-CF patients (chronic carriage) were 
compared to non-CF patients (randomly selected) significant 
differences were found. These occurred in the same 3 phage 
groups. Thus for CF vs. non-CF patients (randomly selected) 
the numbers of S. aureus belonging to phage groups II and non- 
typable phage were significantly greater in CF patients than
non-CF (p < 0.05). The comparison of non-CF patients (chronic
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carriage) and non-CF patients (randomly selected) also 
showed significant differences for the same phage groups 
(p < 0.05). No individual phage group was found to 
predominate.
DISCUSSION
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Clinical Assessment
The clinical progress of the Variable Antibiotic group 
(who received only 1 antibiotic, changed as required) and the 
Flucloxacillin group (who received anti-staphylococcal 
prophylaxis plus an additional antibiotic for 10 days, if 
required) was assessed.
The clinical data revealed no overall significant difference 
between the two groups. All of the patients gained weight and 
height during the 18 months of the investigation, with the 
exception of JG (Variable Antibiotic group) and LM (Flucloxacillin 
group), both of whom experienced weight loss, the more serious 
being that, of LM.
Despite the increases in weight and height, however, only 
2 patients, AT and YH of the Flucloxacillin group showed a 
marked improvement. The weight of AT was increased from lying 
between the 3rd and 10th centiles to between the 10th and 25th 
Gentiles. The height of YH increased from lying between the 
10th and 25th centiles to between the 25th and 50th centiles.
Patient LM whose weight decreased by 2Kg during the course 
of the investigation remained in the severely underweight 
category. According to Kraemer (1978) patients in this
category have the poorest prognosis for survival, and indeed 
this patient died during the investigation.
Although no difference was apparent for weight and height 
between the 2 groups of patients, differences were observed 
between the sexes. The greatest difference was seen in the 
weight charts of the male and female patients. The weight of 
the females was retarded more than that of the males after 10
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years of age. Usually, at this age the pre-puhertal growth 
spurt would he expected to commence in females.
The striking fall in weight after the age of 10 years was 
also observed by Gurivitz ejb aJL. , (1979). Of their female 
patients 67 per cent fell below the 50th centile for weight 
compared to 50 per cent of their male patients. They commented 
that this drop in weight corresponded to a deterioration in 
pulmonary function. They also suggested that this may explain 
why the survival rate for males in CF is greater than that of 
females. Thus the data in this investigation appear to support 
the hypothesis of these two teams of workers that exacerbation 
of pulmonary disease is associated with weight loss which in 
turn results in poor survival.
Pulmonary Changes
The hroncho-pulmonary aspects of the disease did not alter 
radically in either group during the investigation. This applied 
to changes evident both in physical and radiological examinations
Hospital Admissions
The mean rate of hospital admissions decreased in both 
groups during the investigation, thus indicating an improved 
status. This was seen even in patients with advanced pulmonary 
involvement viz. DS and AT. Both of these patients had only 
one admission during the investigation compared to four before 
the investigation.
Thus both regimens of therapy appear to have a significant
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beneficial effect on the rate of hospital admissions. Clearly 
this is useful both in terms of reduced cost to the health 
service and for the general well-being of the child.
Support for the success of these regimens is evident from 
data received after the work of this investigation had ceased. 
Patient DS was admitted three times in the 5 months after this 
investigation whereas patient AT had no further admissions in 
the same period. This was probably due, in part, to the fact 
that patient DS returned to the previous state of specimens for 
culture being taken only at 6 monthly intervals. The parents 
of patient AT, with the aid of their General Practitioner, 
continued the monthly cultures .
Bacteriological Assessment
S. aureus was long believed to be the etiological agent in 
bronchopneumonia in CF patients (di Sant 'Agnese and Andersen, 
1946). This organism was also regarded as being the principal 
cause of lung damage in CF (Lawson, 1970). Recently, however, 
the pathogenic role of P. aeruginosa and H. influenzae have also 
been considered in CF (May ejt a_l. , 1972; Mearns ejb a_l. , 1972; 
H^iby, 1974a; McCrae and Raeburn, 1974).
Assessing both groups of patients collectively in this 
investigation, the results showed that S. aureus was the most 
frequently isolated organism with 75 per cent of patients 
harbouring it. It was followed by H. influenzae (69 per cent) 
and P. aeruginosa (38 per cent). S. aureus and P. aeruginosa 
were isolated with equal frequency (86 per cent) from patients
with advanced pulmonary infection (sputum producers). S. aur eus
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and H. influenzae were isolated with equal frequency (67 per 
cent) from no-sputum producers. Thus for this cohort of patients, 
although S. aureus is the most frequently isolated organism 
overall, in patients with advanced pulmonary disease this 
position is shared with P. aeruginosa. The order of ranking 
the main pathogens associated with CF in this investigation was 
the same as that found by May ejfc aj_. , (1972). H^iby (1974&) 
also found S. aureus was the predominating organism. 90 per 
cent of his patients harboured S. aureus compared to 64 per 
cent with P. aeruginosa and 37 per cent with H . influenzae.
However, Mearns ejt aA., (1972) found that the prevalence 
of S. aureus in their patients decreased with a concomitant rise 
in P . aeruginosa. This pattern occurred in all age groups and 
irrespective of the severity of lung disease.
McCrae and Raeburn (1974) did not isolate S. aureus from 
any of their CF patients. Their investigation assessed 35 CF 
patients attending the Royal Hospital for Sick Children, Edinburgh 
Sputum was obtained from 13 patients. The age range of the 
patients was 1-13 years (median age 6.2 years). They found 
H. influenzae was the predominant pathogen which was replaced 
in older patients by P . aeruginosa.
Perhaps if this investigation had continued for a further 
18 months, P. aeruginosa may also have emerged here as the 
predominant pathogen, especially in the sputum producers.
Despite the predominance of S. aureus in CF, Hjzfiby (1974&) 
and McCrae and Raeburn (1974) believe that P. aeruginosa is the 
principal threat to patients with CF since satisfactory control
of infection by this organism is not possible.
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The absence of P. aeruginosa from the no-sputum producers 
appears to confirm the predilection of P. aeruginosa for the 
CF lung. P. aeruginosa was not isolated from the nose-swabs 
of any of the CF patients, even those who harboured the organism 
in both throat and sputum. This agrees with the findings of 
Laraya-Cussay ejt aA . , (1976).
The ability of other organisms to establish themselves in 
the CF lung was also noted e.g. P r . mirabilis and E . coli.
This seems to lend support to the theory that CF children are 
susceptible from birth to infection of the lower respiratory 
tract by any potential pathogen to which they may be exposed 
(May ^ . , 1972). Thus chemoprophylaxis directed towards 
the prevention of staphylococcal infection may, in fact, be 
contributing to the increase in other infections in CF viz.
P. aeruginosa.
The -Effect of Therapy on Pulmonary Infection.
The results indicated' that the problem of obtaining 
alternative specimens to sputum, which is the specimen of 
choice in CF, could be circumvented by culturing a throat swab 
from patients who were either too young to cough-up sputum or 
could not produce sputum. lacocca _et a_l. , (1963) also
concluded that where sputum was unobtainable from CF patients 
throat swabs were an acceptable substitute.
In this investigation also, S . aureus and P. aeruginosa 
were frequently cultured simultaneously from the throat and 
sputum. This was probably due to the throat being contaminated
by sputum during the coughing which occurs in the CF patient.
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Nose swabs in sputum producers were of little value since they 
reflected neither the flora of the throat nor sputum. However, 
in no-sputum producers the same organism was frequently isolated 
from both nose and throat. This was especially true of S, aureus.
The results of the bacterial flora present in both groups 
at the beginning and end of the investigation indicated that 
the therapeutic regimen of the Flucloxacillin group seemed to 
be more successful in the treatment of S. aureus and H. influenzae 
However, this was only by comparison with non-CF patients and not 
to the other CF patients in the Variable Antibiotic group.
Thus the treatment of the Flucloxacillin group succeeded 
in that the specimens taken from this group at the end of the 
investigation yielded the main bacterial species with a similar 
frequency to that of non-CF patients.
The failure of antibiotic therapy to eradicate P. aeruginosa 
is well documented in the literature (Hoff ejb a_l., 1974;
Shwachman et. 1975). However, both regimens appeared to
keep P. aeruginosa in check since only 1 patient (AT) of the 6 
who harboured the organism was admitted to hospital for therapy. 
Pr. mirabilis was also implicated in the pulmonary infection of 
this patient.
One fact which did emerge was that antibiotic therapy must 
be maintained for at least 10 days. The original five patients 
(TK, A L , IL, D S , YH) were visited weekly and consequently 
frequently had their antibiotic therapy changed weekly.
Recurring infection by the organism being treated was frequent.
When the number of patients being treated rose to the final
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total of 16, visits were made monthly. Therapy was therefore 
maintained for 4 weeks in the Variable Antibiotic group and 
10 days in the Flucloxacillin group. Recurring infection rarely 
occurred. Maintenance of therapy for 2-3 weeks has been advocated 
by Wood e_t ajL. , (1976).
The Role of the Mucoid Strain of P. aeruginosa in CF
P. aeruginosa is frequently isolated from CF patients in 
both a non-mucoid and mucoid form - the latter form is peculiar 
to C F , The ability of P. aeruginosa to establish itself in the 
CF lung is unique since it is rarely a pathogen in other chronic 
pulmonary diseases .
It has been impossible to comment in this investigation on 
the proposed order of infection in CF patients (Burns and May, 
1968; Kilbourn, 1978), since none of the patients were newly- 
diagnosed cases. However, the author was fortunate in 
observing initial colonization by P. aeruginosa in 4 of the 
patients (IL, EB, DS, AT), All of these had established 
pulmonary infection with other bacteria and were sputum producers.
The non-mucoid or rough strain of P. aeruginosa appeared 
first in every patient. This is in accordance with the findings 
of Doggett a_l. , (1966) who observed that a non-mucoid strain 
of P. aeruginosa always proceeded the mucoid form. Two of the 
patients (IL and DS) became colonized with the mucoid form 
between 1 and 6 weeks after receiving aminoglycoside therapy 
(gentamicin). This had raised the possibility that the slime 
envelope may have been produced in vivo in response to amino­
glycoside therapy. However, the mucoid strain was isolated
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from AT who had not been given aminoglycoside therapy. Only 
flucloxacillin had been given to this patient. EB did not 
receive aminoglycoside therapy since the sputum culture yielded 
only a light growth of P. aeruginosa and ^  .Wt
_ to treat this particular infection in order to observe if 
the mucoid strain emerged without an aminoglycoside being 
administered. This patient, therefore, was only prescribed 
cloxacillin and septrin. After harbouring P. aeruginosa for 3 
months no mucoid strains were cultured from his sputum.
One of the reasons proposed for the frequency of mucoid 
strains in the respiratory tract of CF patients was that they were 
selected by means of antibacterial chemotherapy (lacocca et al., 
1963; Govan, 1976).
This was thought unlikely by Doggett je^  aJL. , (1966) since thej? 
reported that mucoid strains were also seen in patients who had 
not received any antibiotic therapy.
Recently, however, Govan and Fyfe (1978) have shown that 
mucoid strains can be isolated in vitro by selection with 
antibiotics. The antibiotics which these workers used were 
tobramycin (an aminoglycoside), carbenicillin and flucloxacillin.
In light of both these findings and those of this investigation, 
it seems very probable that antibiotic therapy plays a part in 
the selection of the mucoid strain of P. aeruginosa in pulmonary 
infection in CF.
Despite the fact that antimicrobial therapy only kept 
P. aeruginosa in check, and did not eradicate the organism, it 
was observed that the quantity of slime envelope surr.ounding each 
colony in vitro was considerably reduced following therapy with
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gentamicin or tobramycin. Therefore treating P. aeruginosa 
specifically is not entirely to no avail. Reducing the amount 
of slime produced by the organism is probably beneficial to the 
patient in that the slime plus the viscous mucus produced by the 
CF lung must contribute to the blocking of the bronchioles.
Antibiotic Sensitivity of pathogens in CF
The comparison of the antibiotic sensitivities of the 
bacterial pathogens between CF and non-CF patients produced 
unexpected results. Many of the pathogens isolated from CF 
patients were more susceptible to some antibiotics than those 
isolated from non-CF patients. This increased sensitivity has 
not been previously reported with the exception of P. aeruginosa. 
The previous comparison for P. aeruginosa was between the 
rough and mucoid strains of this organism which were both isolated 
from CF patients. No comparison has been made between CF and 
non-CF patients. In this investigation increased sensitivity 
was seen in the following organisms:- H. influenzae,
P. aeruginosa, H. parainfluenzas, E . coli, P r . mirabilis and 
St. faecalis.
Two recent reports have commented on the antibiotic 
susceptibility of the mucoid and rough strains of P. aeruginosa 
isolated from CF patients (Govan and Fyfe, 1978; Thomassen ejb a l . 
(1979). Govan and Fyfe found the mucoid strains were more 
resistant to carbenicillin, flucloxacillin, and tobramycin than 
the rough strains but more sensitive to tetracycline, Thomassen 
et al., obtained slightly different results. They reported that 
both strains were resistant to tetracycline and kanamycin.
There was a higher percentage of mucoid strains sensitive to
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gentamicin, carbenicillin, and tobramycin than rough strains.
In this investigation no difference was found in the 
susceptibility of either strain to tetracycline, gentamicin, 
tobramycin, and carbenicillin. Both strains were sensitive, 
although the zone of inhibition surrounding the antibiotic disk 
was usually larger for the mucoid strains than the rough strains 
The mucoid strains were also more sensitive to cotrimoxazole
'i
and sulphonamide than the rough strains. Neither strain was 
sensitive to kanamycin. These results appear to be more 
in agreement with those of Thomassen and co-workers. This may 
be due to the technique employed. This investigation and that 
of Thomassen used the disk diffusion technique whereas Govan and 
Fyfe used the more sensitive single cell technique.
The variation in reports on the sensitivity of rough and 
mucoid strains of F. aeruginosa suggest that at all times 
antibiotic sensitivity tests should be performed before choosing 
the antibiotic for treatment.
The sensitivity of F. aeruginosa to cotrimoxazole and 
sulphonamide by some mucoid strains (notably those from DS) 
was exploited in order to determine if septrin was an acceptable 
alternative to gentamicin or tobramycin. This would have 
provided an oral antibiotic for this organism rather than a 
course of intramuscular injections. However, although the 
organism was sensitive in vitro, septrin was ineffective in vivo 
The failure of septrin to act in vivo is probably due to a 
permeability barrier in the lungs. One of the components of 
septrin, sulphamethoxazole, does not penetrate well into the
bronchial secretions (Reeves, 1971).
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Permeability may also explain the differences between 
CF and non-CF patients in antibiotic susceptibility of the 
other pathogenic bacteria. The pathogens from CF patients 
may be so protected by the mucus in the CF lung and the great 
difficulty of achieving the minimal inhibitory concentration 
of the antibiotic in the lung that, in vitro, deprived of this 
armour, the organisms are more sensitive to antibiotics.
Thus they are not subject to selection pressure in vivo.
H. influenzae from CF patients only differed in their 
sensitivity to ampicillin from that of non-CF patients. Here 
it is the isolates of the non-CF patients which are deviating 
from the expected. These findings for H. influenzae are 
similar to those of Cargill and Saleh (1974). They reported 
that none of the strains of H. influenzae isolated from 
purulent sputum specimens were resistant to ampicillin.
S. aureus showed no variability between CF and non-CF 
patients in sensitivity to the antibiotics tested. All strains 
of S. aureus were sensitive to cloxacillin. Since this 
antibiotic has been given to the CF patients in this investigatio; 
almost from the time of diagnosis, and with little respite, it 
is perhaps surprising that resistance did not develop.
Cloxacillin is a member of the penicillinase-resistant 
penicillins, the first of which was methicillin. Methicillin 
resistance is not as common as would be expected. Perhaps the 
lack of cloxacillin-resistant strains of S. aureus is due to 
similar reasons as that for methicillin. Lacey (1972) reported 
that although the genes responsible for methicillin resistance 
werepiasmid-borne, they were transduced only at low frequency
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and to a narrow range of recipients. Transfer did not occur 
in mixed cultures. He therefore concluded that methicilXin- 
resistant staphylococci probably arose from a single clone.
It has also been reported (Cruickshank jet a_l. , 1973) that 
methicillin-resistant strains do not destroy methicillin or 
cloxacillin (as penicillin-resistant strains destroy penicillin) 
and are capable of growth in the presence of low therapeutic 
doses of methicillin and cloxacillin. Thus the absence of 
cloxacillin-resistance in CF patients is still to be explained.
Antibiotic Resistance Patterns in CF
Most of the reports on resistance patterns (and sensitivity 
patterns) found in CF pathogens have been confined to those of 
S. aureus (Huang et al., 1961; Huang and Sheng, 1963; Hoff 
and H^nby, 197 5) .
Antibiograms which were compiled for all the pathogens 
isolated from the CF patients showed that the number of resistance 
patterns for each pathogen did not depend solely on the actual 
number of times the pathogen was cultured from each group.
P. aeruginosa was isolated on 9 occasions from the 
Flucloxacillin group and from 2 patients, whereas the 105 isolates 
in the Variable Antibiotic group were from 4 patients. However, 
there were 13 times more isolates of H. parahaemolyticus from 
the Variable Antibiotic group than the Flucloxacillin group, 
yet there were only 3 different antibiograms. Also, for 
S. aureus, there was a total of 120 isolates with only 9 anti­
biograms .
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Clearly the number of organisms isolated does not determine 
the number of antibiograms. The possibility of genetic transfer 
of resistance and the effect of long term antibiotic therapy 
should be considered.
The antibiograms found in the isolates from CF patients 
were compared with those of non-CF patients in order to determine 
if resistance to certain antibiotics was linked and perhaps 
commonly found in the local population. However, there was 
little evidence to support this idea, especially amongst the 
gram-negative pathogens. The antibiograms for these organisms 
tended to be unique for the patient who harboured the organism. 
The gram-negative pathogens (P . aeruginosa, P r . mirabilis,
E . coli) showed evidence of cross-resistance i.e. bacteria 
resistant to one member of a group of antibiotics are usually 
resistant to the others, especially if the chemical composition 
is very similar.
P r . mirabilis isolated from patient AT exhibited very well 
how resistance arises from the use of antibiotics. This 
organism was originally only resistant to colistin. Following 
therapy with septrin it rapidly developed resistance to 
sulphonamide and t r L ; (the components of septrin),
Cephradine was then substituted for septrin. Resistance to 
cephradine developed following 3 months continuous therapy with 
this antibiotic. It seems highly probable that either R-factors 
or transduction were responsible for the acquisition of 
resistance to these drugs.
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S. aureus showed evidence of linked resistances. Of 
the S. aureus isolated 92 per cent were resistant to penicillin.
As the CF patients were regularly in contact with the hospital 
environment, resistance to penicillin was expected. Resistance 
is due to the production of p-lactamase. Since ampicillin is 
also susceptible to this enzyme, the organism was assumed to be 
resistant to this antibiotic if it was also resistant to 
penicillin since it too is susceptible to the action of 
lactamase. This was irrespective of the zone of inhibition 
surrounding the ampicillin disk.
Resistance to penicillin, and in many instances, antibiotic 
resistance in staphylococci is due to the acquisition or presence 
of plasmids (Novick and Bouanchaud, 1971). Plasmids are also 
responsible for resistance to tetracycline, erythromycin, 
neomycin, and fusidic acid (Lacey, 1971a; Lacey, 1971b; Lacey 
and Grinsted, 197%; Lacey and Rosdahl, 1974).
Linked resistances for some antibiotics have been reported. 
These are penicillin and erythromycin (Mitsuhashi e_t , 1965); 
and neomycin, kanamycin, and erythromycin (Annear and Grubb,1972).
. In this investigation linked-resistance to neomycin, 
kanamycin, and erythromycin in the same antibiogram occurred 
in 3 per cent of all strains isolated, as was resistance to 
neomycin and kanamycin, and erythromycin and neomycin. All 
of these strains were also resistant to penicillin and ampicillin. 
Linked resistance to penicillin and erythromycin was encountered 
in 7 per cent of isolates.
No information could be found in the literature of anti­
biotic resistance patterns for the haemophilus species, including
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H. influenzae. Resistance in these organisms may he due in 
part to natural resistance e.g. cloxacillin. All haemophili 
are resistant to this antibiotic.
If the data from the sensitivity and resistance patterns 
are compared with the original pre-designed sequence of anti­
biotics (Table 3) for treating S, aureus, H. influenzae and 
P . aeruginosa, it can be seen that the order of choice was 
correct. The pre-designed sequence could therefore be used 
with reasonable confidence in choosing an appropriate anti­
biotic for treatment before the full results of the antibiotic 
sensitivity tests are available.
Phage-types of S. aureus from CF patients
Previous authors had stated that the S. aureus of the B o / B l  
complex were more frequently isolated from CF patients than non- 
CF patients with chronic respiratory infections (Huang and 
Sheng, 1963). There was no evidence of greater frequency of 
this phage-type in this investigation. Only patient EB was 
colonized with S . aureus of the 80/8I complex.
This is in agreement with other authors who found no 
predominant phage pattern for patients with CF (lacocca _ejb al., 
1963; Hoff and H^iby, 1975) . However, Hoff and Hjzfiby reported 
that S. aureus of the "epidemic complexes" 80 and 83A were 
isolated in significant numbers. But this was not found in 
the present investigation.
Although predominance of S. aureus of one particular phage- 
type was not found, persistance of S. aureus of the same phage-
group was observed in CF patients. This was also found by
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lacocca _et a_l,, (1963). Most of the patients were colonized 
by S. aureus belonging to one phage-group or of a particular 
phage-type within that group. This pattern was also seen in 
the non-CF patients (chronic carriage). The CF patients who 
were colonized by S. aureus belonging to one phage-group were 
persistant carriers of the organism (LC, E B , AT, D B , LM, DA).
This persistance of one phage-group may be due to the 
phenomenon of bacterial interference between strains of S. aureus 
(Shinefield e_t a_l. , 1974). These workers found that super­
infection by other strains of S. aureus was not established 
in patients who were carriers of S . aureus. Shinefield and 
co-workers also found that interference between strains of 
S. aureus was site-specific i.e. throat or nose.
It was postulated at the start of this investigation that 
as the nares are the most common source of S. aureus in humans 
the lungs of CF patients may become infected with their own 
strain of organism i.e. could the S. aureus progress from the 
nares—> throat—  ^sputum ? Only patient DS yielded S . aureus 
from all three sites in specimens taken on the same day.
Although the S. aureus belonged to the same phage-group (III), 
the phage-types were all different. Thus there was no evidence 
to support the migration hypothesis.
Patients who could produce sputum also rarely yielded 
S. aureus in their nose or throat swabs. If this organism was 
isolated it was from the sputum only. Thus the upper respiratory 
tract does not appear to be the source of S . aureus in pulmonary 
infection in the CF patient. The frequency of isolation of
non-typable strains (33 per cent) was that expected in patients
98
receiving antibiotic therapy (Anderson and Williams, 1956).
Although no predominant phage-types were found, a significai 
difference was found in the number of strains belonging to phage- 
group II in both CF patients and non-CF patients (chronic 
carriage) compared to those of non-CF patients (randomly 
selected). This phage-group contains S. aureus which cause 
vesicular and exfoliative skin lesions.
No correlation between phage-type and antibiotic sensitivity 
pattern was found.
Conclusions
Thus it can be concluded that monthly bacterial cultures 
of nose, throat and sputum can contribute to maintaining the 
clinical status of the CF patient; even if an overall clinical 
improvement was not apparent in the small series of patients 
studied here.
Both methods of therapy, when applied consistently, are of 
value. The regimen of the Flucloxacillin group was slightly 
more effective than the Variable Antibiotic group, especially 
in controlling S. aureus and H . influenzae. However, the 
final frequency with which these organisms were isolated was 
not significantly different from that of the Variable Antibiotic 
group. This therefore casts doubt on the value of anti- 
staphylococcal prophylaxis. The Flucloxacillin group, it will 
be remembered, received continuous therapy with flucloxacillin.
The results also indicated that bacteriological examination 
of the patient at 6-month intervals is quite inadequate. It is 
not the antibiotic regimen which is important, but rather the 
frequency with which infection is monitored, so that appropriate 
antibiotics can be administered when required.
In retrospect it would probably have been more efficient 
to have had lung function tests performed at the beginning and 
end of the investigation. However, these were not made available
From the literature it is apparent that the practice of the 
past 20 years of controlling infection with the varied use of 
antibiotics has had only a limited success. Thus it is true 
that CF patients are now living longer and have a better quality 
of life, but complete eradication of infection has never been 
achieved. The doubts cast concerning the value of anti- 
staphylococcal prophylaxis suggests that any future investigation 
should consider including a control group which does not receive 
prophylaxis and only an antibiotic in response to a specific 
infection.
REFERENCES
100
ANDERSEN, D.H. (1938). Cystic fibrosis of the pancreas and its 
relation to coeliac disease: a clinical and pathologic study.
American Journal of Diseases of Children 56 ; 344-399.
ANDERSON, E.S. and WILLIAMS, R.E.O. (1956). Bacteriophage 
typing of enteric pathogens and staphylococci and its uses 
in epidemiology. Journal of Clinical Pathology 9: 94-127.
ANNEAR, D.I. and GRUBB, W.B. (1972). Linked and unstable
resistance to kanamycin and penicillin, and diffusible pigment 
production, in an isolate of Staphylococcus aureus.
Journal of Medical Microbiology _5; 109-111.
BIGGAR, W.D., HOLMES, B. and GOOD, R.A. (1971). Opsonic defect
in patients with cystic fibrosis. Proceedings of the 
National Academy of Sciences 68 ; 1716-1719.
BLACKFAN, K.D. and MAY, C.D. (1938). Inspissation of secretion,
dilatation of the ducts and acini, atrophy and fibrosis of the 
pancreas in infants. A clinical note. Journal of Pediatrics
627-634.
BOXERBAUM, B. , KAGUMBA, M. and MATTHEWS, L.W. (1973). Selective 
inhibition of phagocytic activity of rabbit alveolar macrophage 
by cystic fibrosis serum. American Review of Respiratory 
Disease 108: 777-783.
BURNS, M.W. and MAY, J.R. (1968). Bacterial precipitins in serum 
of patients with cystic fibrosis. Lancet(i): 270-272.
CARGILL, S.J. and SALEH, F.V. (1974).' Sensitivity patterns of 
respiratory type Haemophilus influenzae from purulent sputum 
specimens. Scottish Medical Journal 19: 253-256.
CARLSON, D.M. and MATTHEWS, L.W. (1966). Polyuronic acids
produced by Pseudomonas aeruginosa. Biochemistry 5: 28l7«2822.
101
COWAN, S.T. and STEEL, K.J. (1974). Manual for the Identificatioi 
of Medical Bacteria . Cambridge University Press.
CRUIKSHANK, R., DUGUID, J.P., MARMION, B.P. and SWAIN, R.H.A.
(1973). Medical Microbiology Vol. I : Microbial Infections
p. 240-241. Churchill Livingstone. Edinburgh and London.
DI SANT’AGNESE, P.A. and ANDERSEN, D.H. (194&). Chemotherapy in 
infection of the respiratory tract association with cystic 
fibrosis of the pancreas. American Journal of Diseases of 
Children 72: 17-61.
DI SANT'AGNESE, P.A. and TALAMO, R.C. (1967). Pathogenesis and 
pathophysiology of cystic fibrosis of the pancreas. New 
England Journal of Medicine 277: 1287-1294, 1344-1352, and 
1399-1408.
DOERSHUK, C.F., MATTHEWS, L.W., TUCKER, A.S., NUDELMAN, H.,
EDDY, G. , WISE, M. and SPECTOR, S. (1964)-. A five year 
clinical evaluation of a therapeutic program for patients 
with cystic fibrosis. Journal of Pediatrics 6 5: 677-693. 
DOGGETT, R.G., HARRISON, G.M. and WALLIS, E.S. (1964). Comparison 
of some properties of Pseudomonas aeruginosa isolated from 
infections in persons with and without cystic fibrosis.
Journal of Bacteriology 87: 427-431.
DOGGETT, R.G., HARRISON, G.M., STILLWELL, R.N. and WALLIS, E.S.
(1965). Enzymatic action on the capsular material produced 
by Pseudomonas aeruginosa of cystic fibrosis origin.
Journal of Bacteriology 89: 476-480.
DOGGETT, R.G., HARRISON, G.M., STILLWELL, R.N. and WALLIS, E.S.
(1966). An atypical Pseudomonas aeruginosa associated with 
cystic fibrosis of the pancreas. Journal of Pediatrics
68: 215-221.
102
EICHENWALD, H.F. (i960). Staphylococcal infection in CF. In
Research on Cystic Fibrosis, pp. 89-120. Edited by R.McIntosh. 
Baltimore: The French-Bray Printing Company.
EVANS, L.R. and LINKER, A. (1973). Production and characteriz­
ation of the slime polysaccharide of Pseudomonas aeruginosa. 
Journal of Bacteriology 116: 915-924.
FANCONI, G., UEHLINGER, E. and KNAUER, C. (1936). Das
Coeliakiesyndrom bei angeborener zystischer Pankreasfibromatose 
und Bronchiektasien. Wiener Medizinische Wochenschrift 
753-756.
FARBER, S. (1945). Some organic digestive disturbances in 
early life . Journal of the Michigan Medical Society 44: 
587-594.
FINNEY, D.J., LATSCHA, R., BENNETT, B.M. and HSU, P. (1963).
Tables for Testing Significance in a 2 x '2 Contingency Table. 
Cambridge University Press.
GIBBONS, A., ALLAN, J.D., HOLZEL, A. and McFARLANE, H. (1976). 
Cell-mediated immunity in patients with cystic fibrosis.
British Medical Journal 1: 120-122.
GIBSON, L.E. and COOKE, R.E. (1959). A test for concentration 
of electrolytes in sweat in cystic fibrosis of the pancreas 
utilizing pilocarpine iontophoresis. Pediatrics 23: 545-549. 
GOVAN, J.R.W. (1975). Mucoid strains of Pseudomonas aeruginosa: 
The influence of culture medium on the stability of mucus 
production. Journal of Medical Microbiology 8: 513-522.
GOVAN, J.R.W. (1976). Antibiotic therapy and cystic fibrosis; 
increased resistance of mucoid Pseudomonas aeruginosa to 
carbenicillin. Journal of Antimicrobial Chemotherapy 2:
215-217 .
103
GOVAN, J.R.W. and FYFE, J.A.M. (1978). Mucoid Pseudomonas
aeruginosa and cystic fibrosis: resistance of the mucoid form 
to carbenicillin, flucloxacillin and tobramycin and the 
isolation of mucoid variants in vitro. Journal of Anti­
microbial Chemotherapy 4: 233-240.
GURIVITZ, D., COREY, M. , FRANCIS, P.W.J., CROZIER, D. and
LEVISON, H. (1979). Survival. In Perspectives in Cystic 
Fibrosis. Pediatric Clinics of North America 26: 603-615.
HALBERT, S.P., DI SANT'AGNESE, P.A. and KATEK, F.R. (i960).
Staphylococcal antibodies in cystic fibrosis of the pancreas. 
Pediatrics 26: 792-799.
HALBERT, S.P. (1967). Immunological aspects of cystic fibrosis. 
Modern Problems in Pediatrics 10: 144-157.
HOFF, G.E. SCHI0TZ, P.O. and PAULSEN, J. (1974). Tobramycin 
treatment of Pseudomonas aeruginosa infections in cystic 
fibrosis. Scandanavian Journal of Infectious Diseases 6: 
333-337.
HOFF, G.E. AND H0IBY, N. (1975). Staphylococcus aureus in 
Cystic Fibrosis: Antibiotic sensitivity and phage types
during the latest decade. Acta Pathologies et Microbiologica 
Scandinavie^ B 83: 219-225.
H0IBY, N. and AXELSEN, N.H. (1973). Identification and quantit­
ation of precipitins against Pseudomonas aeruginosa in patients 
with cystic fibrosis by means of crossed immunoelectrophoresis 
with intermediate gel. Acta Pathologies et Microbiologica 
Scandinavica B 8l: 298-308.
104
H0IBY, N, (1974a). Epidemiological investigations of the 
respiratory tract bacteriology in patients with cystic 
fibrosis. Acta Pathologies et Microbiologies Scandinavica _B
541-550.
H0IBY, N. (1974b). Pseudomonas aeruginosa infection in cystic 
fibrosis. Relationship between mucoid strains of P s . 
aeruginosa and the humoral immune response. Acta Pathologies 
et Microbiologies Scandinavica _B 551-558 .
HUANG, N.N., VAN LOON, E.L. and SHENG, K.T. (1961). The flora 
of the respiratory tract of patients with cystic fibrosis of 
the pancreas. Journal of Pediatrics 59: 512-521.
HUANG, N.N. and SHENG, K.T. (1963). Staphylococcal carrier rates 
of patients with cystic fibrosis and of members of their 
families. Journal of Pediatrics 62: 36-43.
lACOCCA, V.F., SIBINGA, M.S. and BARBEVO, G.J. (I963).
Respiratory tract bacteriology in cystic fibrosis. American 
Journal of Diseases of Children IO6: 315-324.
KILBOURN, J.P. (1978). Bacterial content and ionic composition 
of sputum in cystic fibrosis. Lancet(i ); 334.
KRAEMER, R., RUDEBERG, A., HADORN, B. and ROSSI, E. (1978). 
Relative underweight in cystic fibrosis and its prognostic 
value. Acta Paediatrics Scandinavica 67: 33-37.
LACEY, R.W. (1971a). High-frequency transfer of neomycin
resistance between naturally occurring strains of Staphylococcu 
aureus. Journal of Medical Microbiology 4: 73-84.
LACEY, R.W. (1971b). Transfer of tetracycline-resistance
between strains of Staphylococcus aureus in mixed cultures. 
Journal of Medical Microbiology 69: 229-237.
105
LACEY, R.W. (1972). Genetic control in methicillin-resistant 
strains of Staphylococcus aureus. Journal of Medical 
Microbiology _5: 497-508.
LACEY, R.W. and GRINSTED, J. (1972). Linkage of fusidic acid 
resistance to the penicillinase plasmid in Staphylococcus 
aureus. Journal of General Microbiology 73i 501-508.
LACEY, R.W. and ROSDAHL, V.T. (1974). An unusual "penicillinase
plasmid" in Staphylococcus aureus; evidence for its transfer 
under natural conditions. Journal of Medical Microbiology 
7; 1-9.
LARAYA-CUASAY, L.R., CUNDY, K.R. and HUANG, N.N. (1976).
Pseudomonas carrier rates of patients with cystic fibrosis 
and members of their families. Journal of Pediatrics 89:
23-26.
LAWSON, D. (1970). Bacteriology of the respiratory tract in
cystic fibrosis - a hypothesis. In The Control of Chemotherapy, 
pp. 69-77. Edited by P.J. Watt, Livingstone: Edinburgh.
LINKER, A. and JONES, R.S. (1964). A polysaccharide resembling 
alginic acid from a Pseudomonas micro-organism. Nature 
204: 187-188.
McCRAE, W.M. and RAEBURN, J.A. (1974). The patterns of infection 
in cystic fibrosis. Scottish Medical Journal 19: 187-190.
McFARLANE, H. , HOLZEL, A., BRENCHLEY, P., ALLAN, J.D., WALLWORK, JI 
SINGER, B.E. and WORSLEY, B. (1975). Immune complexes in 
cystic fibrosis. British Medical Journal 1; 423-428.
MARTIN, D.R. (1973). Mucoid variation in Pseudomonas aruginosa 
induced by the action of phage. Journal of Medical 
Microbiology 6: 111-118.
106
MARTINEZ-TELLO, F.J., BRAUN, D. and BLANC, W.A. (1968). Immuno­
globulin production in bronchial mucosa and bronchial lymph
nodes, particularly in cystic fibrosis of the pancreas.
Journal of Immunology 101: 989-1003.
MAY, R.J., HERRICK, N.C. and THOMPSON, D. (1972). Bacterial 
infection in cystic fibrosis. Archives of Diseases of 
Childhood 47: 908-912.
MEARNS, M.B., LONGBOTTOM, J.L. and BATTEN, J.C. (1967).
Precipitating antibodies to Aspergillus fumigatus in cystic
fibrosis. Lancet(i): 53B-539.
MEARNS, M.B., HUNT, G.H. and RUSHWORTH, R. (1972). Bacterial
flora of the respiratory tract in patients with cystic fibrosis 
1950-1971. Archives of Diseases of Childhood 47: 902-907.
MITCHELL-HEGGS, P., MEARNS, M.B. and BATTEN, J.C. (1976).
Cystic fibrosis in adolescents and adults. Quarterly Journal 
of Medicine 1_5: 479-504.
MITSUHASHI, S., HASHIMOTO, H., KONO, M. and MORIMURA, M. (1965). 
Drug resistance of staphylococci. II Joint elimination and 
joint transduction of the determinants of penicillinase 
production and resistance to macrolide antibiotics. Journal 
of Bacteriology 89: 988-992.
NOVICK, R.P. and BOUANCHAUD, D. (1971). Extrachromosomal nature 
of drug resistance in Staphylococcal aureus. Annals of the 
New York Academy of Sciences l82: 279-294.
POLYMENIDIS, Z., LUDWIG, H. and GOTZ, M. (1973). Cystic fibrosis 
and HLA antigens. Lancet(i): 1452.
REEVES, D.J. (1971). Sulphamethoxazole/trimethoprim: the first
two years. Journal of Clinical Pathology 24: 430-437.
107
SCHAAP, T. and COHEN, M.M. (1976). A proposed model for the
inheritance of cystic fibrosis. In Cystic Fibrosis:
Projections Into the Future, pp. 291-302. Edited by J.A.
Mango and R.C. Talamo, Stratton: New York.
SCHWARTZ, R.H., JOHNSTONE, D.E., HOLSCLAW, D.S. and DOOLEY, R.R. 
(1970). Serum precipitins to Aspergillus fumigatus in 
cystic fibrosis. American Journal of Diseases of Childhood 
120: 432-433.
SCHWARZMANN, S. and BORING, J.R. (1971). Antiphagocytic effect 
of slime from a mucoid strain of Pseudomonas aeruginosa. 
Infection and Immunity 3.’ 762-767.
SHINEFIELD, H.R., RIBBLE, J.C., BORIS, M., EICHENWALD, H.F., ALY,R 
and MAIBACH, H. (1974). Bacterial interference between 
strains of S . aureus. Annals of the New.York Academy of 
Sciences 236: 444-455.
SHWACHMAN, H,, KHAW, K-T. and KOWALSKI, S.M. (1975). The 
management of cystic fibrosis. Observations on gentamycin 
when used with other antibiotics in pulmonary infections 
associated with cystic fibrosis. Clinical Pediatrics 14: 
1115-1118.
SORENSEN, R.V., STERN, R.C. and POLMAR, S.H. (1977). Cellular 
immunity to bacteria; Impairment of in vitro lymphocyte 
responses to Pseudomonas aeruginosa in cystic fibrosis 
patients. Infection and Immunity l8; 735-740.
SPROUL, A. and HUANG, N.N. (I964). Growth patterns in children 
with cystic fibrosis. Journal of Pediatrics 65: 664-676.
STEINBERG, A.G. and MORTON, N.E. (1956). Sequential test for 
linkage between cystic fibrosis of the pancreas and the MNS
locus. American Journal of Human Genetics S: 177-189.
108
TANNER, J.M., WHITEHOUSE, H.R. and TAKAISHI, M. (1966).
Standards from birth to maturity for height, weight, height 
velocity and weight velocity: British Children 1965. Part I
Archives of Diseases of Childhood 41: 454-471. Part II
Archives of Diseases of Childhood 41: 613-635.
THOMASSEN, M.J., DEMKO, C.A., BOXERBAUM, B., STERN, R.C. and
KUCHENBROD, P.J. (1979). Multiple isolates of Pseudomonas 
aeruginosa with differing antimicrobial susceptibility 
patterns from patients with cystic fibrosis. Journal of 
Infectious Diseases I4O: 873-880.
TURNBULL, L.S., TURNBULL, L.W., CROFTON, J.W. and KAY, A.B. (1977) 
Immunoglobulins and complement in sputum from chronic 
bronchitis and other pulmonary diseases. Lancet(ii): 526-529.
VIRTANEN, S. (1966). Salivary secretion of ABH blood group 
substances in cystic fibrosis of the pancreas. Journal of 
Pediatrics 68: 139-141.
WALLWORK, J.C., BRENCHLEY, P., MCCARTHY, J., ALLAN, J.D., MOSS, D. 
WARD, A.M., HOLZEL, A., WILLIAMS, R.F. and McFARLANE, H. (1974) 
Some aspects of immunity in patients with cystic fibrosis. 
Clinical and Experimental Immunology 18: 303-320.
WARWICK, W.J. and POGUE, R.E. (1977). Cystic Fibrosis: An
expanding challenge for internal medicine. Journal of the 
American Medical Association 238; 2159-2162.
WILLIAMS, R.J. and GOVAN, J.R.W. (1973). Pyocine typing of 
mucoid strains of Pseudomonas aeruginosa isolated from 
children with cystic fibrosis. Journal of Medical Micro­
biology 6; 409-412.
WOOD, R.E., BOAT, T.F. and DOERSHUK, C.F. (1976). Cystic
Fibrosis. American Review of Respiratory Disease 113: 833-878,
APPENDICES
109
gI
D9
I I
^  *o
CQ
u
'c!
•H
I
'BÜI0SÆlîdTBa 
STS'Bq.o e f q o u o a ^
aiTII03[OT-qJl
lie#
X-Bxqouooa:
eTS'Bq-O0Xsq-'V
noT^eTjarae&fB
STBÆq.C[OÏÏI0'lBH
'80OiicUCqo'Ba
'B0onds^
STSOTXB^O
suoTq.'Bq.Td0a:o
TXÎOXIOXÎÏÏ
Sttrqqnio
TB^T^tG
Tmqndg
■q^ tiop
qu0ms8088y
qu0Tqea
dnoaif)
I
Î2Î ÎS3
I >> 1 I I I II II II IIÎ5Î
I ' ^ l l  + +  II II I I + +
I 5 II II I I +1 I II II
<
lîsi II + +  II II II + I
<ilsi II II II II II + +
|z; *H "H + + 4" $
t t I I
Ph H Ph
g  S
H
I II I {Si I -H + + + +
 ^ ^*1^ 1*^ *r4 pH *p| f—4 f—% *r4 «mI
■p tô -p. C3 -P
•l 'â'I
Ü @  @ 8  ^
+ + + + + t 1 I
Î Î t t 1 1
t + + + Î Î + +
3
i l M U M
(DI§
I
t
I
I 
+
I
I 
-H
II
I 
I
aI
1
I
110
CM
I
EQ
0) pR
•HS’rHO
Ph
01I
ft Ü
rHO
m
i Û
1•H
 ^Ift
'Ennesjîqdnia;
STS'Bq.oaTqouojcG
SaTii03[OTqji
T i m
t'BxqouoÆG
8T8SqO0%0%Y
UOT g.'BXjtrp20djCB
STSjCqdomo-BH
■e80udjCqoi3ji
'B0oudsjC(i
STSOtTB^O
suoTq.'Bq.Td0ÆO
•pqoiïoxîa
toqqin.io
l'Bq-T'^Œ
umq-ndg
q ^ O Q
qu0ïïiss0ssv
qxi0Tq.'Ba:
dnoÆ-^
I I I
I I I
I I +
I I I
+ + Il + +
I I I
I I  I +
I 44 44 -H
44 I I I
4- î 4-1
II II
4-4- I 41
4- 4- I l
4- 4- 44 44
•H rH i—j•S+= tô -P rà -P
îs;  ^ t t  ^l2î
|si îsi 
|z| S 
!si 5 
^ S
t t
I 4-
I I
I + 
+ + 
+ t
I 44 
4- t 
I
.4, Î Î
■H -H î Î
Q
|z; ^
^  |si 
îsi {Si
cô c3 , cô . (ü ci ceH rH "H rH *H rH "H rH ‘H rH *H rH
rH rH rH 
-P c3 -p 03 -P
a l  agi à l  â l  a l  à l
g 8
î
(DI
S
I
+
I
44
S
II
I4J
§
III
§I
-P
m
I
Ia
Isg
I
I
fcj
0>
0
03
•H
1
I%
03
0)
•H
i
-r
•HI
03
Ü
•H
■ë
•Ha
*R
0>
03
'I
i
1
'CJ
0•H
■g•Ha
1
0
■p
!
•H
1
CO
03
0)3
a
tH
O
g
rO
I
CO3oo
I
I
I
I
M
a
%
I
1c
o
03
1!
03
I
I
ë
03
-I
03
1
Ië
_ 03
II
03
1
•H
ë
•Saa
I
.3Is
-p4
o  o
O  O  CM O  
rH  rH  0 \  i—I
CT\ KN
EH 00 EH 00 CO op CO 00 CO CO 00
0 \ r H 00 CO CO m
EH EH 
ÎSÎ 5
K\ rH
CT\ cr\
EH EH
CO O
O  O  O O CT\^ "^
rH rH CO VOO  VO
VO VO EH VO EH VO VO VO VO VO VO VO VO VO VO VO VO EH EHVO .VO VO VO VO
VO VO OV
\o  VO irv
o  o
VO VO O O LT\
LTV LTV 
rH.rH
LTMTMrs EH 
rH .rH rH
lov irv 
I—1.1—I
LTMTV LT\ LTV 
rH rH .pH .rH
LPi irv 
I— I rH
LT\ ov ov o ir\vo ITMTVLCV I—! I—I I—Î I—I O  CO
O  O  
O  O  VO 
rH rH OV rH
ov 00 _ 
VO o v o
VO in
CJVCM
CM CM CM CM CM EH m.LOt.m CM CM CM CM LT\ LOmirv
CM CM O  CM 
irv LTMTvirV
O  K\ 
LTV rHLTV LT\
CM CM CM CM CM EH KV KV KV CM CM CM KV.KVrrv CM CM CM CM CM CM KVKV KV
K V K \
CM CM O  O  CMrOi CM CM CM KV KV KN CM CM CM CM KV t r \  hT\ r r \KV K \
O  O
O  O  l>-CO
I—I I—I OV CT\
o o o
CM CM CM Eh 
rH rH .rH
o  o  o
CM CM CM 
rH rH
O O O O 
CM CM CM CM 
rH .rH .rH .rH
O  O  
CM CM 
I—I I—I
CM CM
00 00 O  O  OV 
CM CM 
I—I I—I
O  O  VO 00 
CM CM rH iH 
[—I I—1
CM CM
O  rH
■§ 1 4  4
“f
1 1 1 .  g
I
l l i
o  o  o
0  rH rH O  
ft rH 'ri 'H
H  -H O  3  O d 0FH ft
O  O e EH
0
1 0 4
iH 0 ft
P rd 0 0k •H o 0o iH *dçâ O •HU H -P
-P o ft ft0 0 0
Eh o ft
01I
0
1
p
I
rH
1
0
0
rH
■§
I
1
I
0  
-P
4
41
0
•¥>I
rd
0
+=
0
0
-P
I
0
4
EH
a
Ill
o•HPc3
p00
a
0/dP
q•H
0PFI0•HP
ft
ftO
m
s<+H 00 PFI Fl0 0ElO •HO P.FI o3P ftcd
ft ftO0rd FlP OP«HO
00•HP•H>•HP*H0Fl00
O•iH
PO•H,Q•HP
0
0
•H
•H
1
0-p
1
102
0
0
I
4
■s
M
H
•s
I
0
I
i
1
0
Igë
0
IS
1
0
I
ië
Ü•H
■g
■H
-p
.3
45
I
o o %-^o 
O O 0\ O o1—I I—I
<T\OV 00 CTvO
8 888 
I I I—1 I—I l —I
0\ CT\ ON ON
O O O O O O O O I—I rH I—Il—I O  1—I
ON ON ON ON O rH
O OO O KV o %—XI—I rH ON I—I O 8  8 8 8  I—1 I—I fH I—I
o o o oO  O O O
I— I rH I— 1 rH O  ^
CO 00 CO • .CvJ.OJ.CNI EH
CO 00 VO'CO'O !25 CM OJ CM CM
00 CO 00 CO CM CM CM CMCO 00 CO 8.8CM CM CM
00 CO 00 00 CO CO 00 CM CM CM CMCM CM CM
O O sO O O CO I—I I—I tCN rH O
.00^ 0 œ m m  EH 
CO CO KNOO o
oo 'T-x o O O O O OirvOOCO O O O OC rH rH GO i—! i—I rH i—I O i—I
^  .00^ 0^ 0 EH
VO COCOO- CO 00 00 CO OrH
iH rCN
O  KN
0  
1— 1 0
rH
rH
•H 4 0
O  rd O  ^ fliH flN *5 *d 0 •H rH •Hd a Fl -H rH •H rHH 0 0  rH rH Ü Oo fl ftH ■H •H ka g rH *H O Fl O
•H fl >3 O 0 0 0
^  ft a M «P flP H fl ft o H Po d 0  a rH 0 0o m pq 4 O o EH
4 4  § 
■g g |N rH (3
IIIo o  o
4
•g•H
■g
o
1 1  g 4•H h)*H O
-P . .
0 O 0 
Ü  Eh îs i
I
I
0arH
p  *d  t>3 *H
I
0
*§•H
O•H
•g•H
P
0
I
PI
*d
0p
0
0P
1
0
I
a
EH
g
*H
I
■g
I
I4
0
I
ie
I
tJ
0
1O  üi ra P 
•H fl 
0
IIg) d,
t
I%
0
4
I
4
i
0
O
•H
P
O
•H
4
P
I
1
ft
g
«H
0
1I
0
I g
1
0
IIë
0
1
•H
P
0 ON ON
ft
1— 1 1— 1
ft ^ J H N
9 O  O
1
KN KN
0
Ii
ë
0
II
1
0
Ig
ë
0  
•H
•g
•H
41
4
P
0  
•H
41
B  CM EH (M ir\ • tnCM CM CM CM CM m.uMn EH EHCM CMLTV.LfN irv.LTv
irvcM m  
LTi CM
00 CM
00 CT\
CM CM
KV KN
KN KN
CM 00
ON ON
ON IfN
4
0
o  ^o  00
rH KN
s|=i
CM
O  NO
O n rH
'=T ■sj' -«M- 
CM CM CM
• 00 *00 Eh-^Eh-^ 
• rH o rH 
|2i KN Is; KN
KN
A
EH
NO
CM
NO
CM
ON 00 ON rH ON
KN KN KN
KN CM KN
8 8 8 8  
rH rH rH rH
CM CM CM CM
ON
ITN
O  CM 
NO 00
KN KN KN 
♦ KN • KN KN • 
Eh j H  Eh j H  I—( Eh
00 l2i O tT" 00
• ON o ON 
EH jH  EH jH
!s! vo
iH
i i .ftrHPp» llê„
8
l>- KN 00
(ON ON ON
KN KN KN
KN KN KN
(ON KN O
CM CM KN
O O x — s
O O  ON
rH 1— 1 ON ON
KN KN KN KN
KN KN KN KN
rH .tH I rH
\
KN KNCM 1 LTN
KN KN KN CM
H rH rH rH
O  O  O  O  r— s
O  O  O  O  tfN
rH rH rH rH ON
LfN
ON 00
(ON C3N ON (ON ON (ON ON 
rH rH .rH rH
ON 00 NO (ON CN (ON 00 
rH rH rH rH
I I I
ft ft ft 
0 0 0 O O O
E h Eh
5 îs;
Eh EH
5 S
rH  NO
sh "sj-
CM CM CM CM
^  o
E h JM Eh j M CM CM CMCM CM EH E h
^  ^ Î2î ^NO o ^ N O  
CM CM rHrH H
 Eh E h
5 Î2Î
EH EH 
5  ^
CO EH R
0
rHI
I
I
4 
g
5
p
0
a
I
>d
0
g
4
1
0
I
4
EH
s
